
The Relationship of Haemostatic System to the Vessel Wall, Thromboembolism, Atherosclerosis from Pathogenesis and Laboratory Standpoints

Orhan N. ULUTIN

Professor of Medicine, Honorary Member of Turkish Academy of Science, Cerrahpaşa Medical School,
University of İstanbul, İstanbul, TURKEY

Turk J Haematol 2002;19(1):7-29.

Received: 13.06.2001 **Accepted:** 03.09.2001

In this review, I am going to discuss the vessel wall in normal and pathologic conditions from Haemostasis and Thrombosis standpoints, and also summarize our laboratory findings related to the Haemostatic System [1,2,4,45,67,68,70,127,128,130,162,163,193,199,200,217,247]. Vessel wall alteration was first time cited by Imhotep of ancient Egypt few thousand years ago. He showed the different appearance of vessels in young and old people during mummification and this was written down on papyrus as well on the rocks [146]. The first document related with haemophilia existed almost in the same area; in Babylon Talmut. So bleeding disorders and atherosclerosis and thrombosis were known in ancient times. The alteration was cited as degenerative process by Imhotep. In 1833 J.F. Lobstein and

then in 1904 F. Marchand named the disease as "Arteriosclerosis" and "Atherosclerosis" in the last millennium [145]. There are various hypothesis on the pathogenesis of the disease. In recent years many hypothesis, theories and experimental studies on atherosclerosis were published and the pathogenesis of the disease was investigated in biochemical, molecular biologic and molecular genetic perspectives. Most of the studies published in recent years were on lipid changes, genetic defects to receptors; these studies were in strong, correlation between lipoprotein metabolism and development of atherosclerosis.

We are going to present our data related with haemostatic view which really began more than 150 years ago by Rokitsansky [147]. This depends

on abnormal deposition of blood components including fibrin in the intima. This view is supported with some addition by Duguid in 1946^[71]. He proposed that thrombosis was a factor for the pathogenesis of coronary Atherosclerosis. In 1856 Virchow proposed tissue response to endothelial injury theory and this theory got more support in the following years^[148]. Depending on the response to injury theory, in 1976 Ross and Glomset developed this hypothesis and described endothelial injury caused by recurrent denudation of Endothelial Cells (EC) due to smoking, hypertension, hypercholesterolemia, and recurrent mural thrombosis^[65,149]. Platelets also activate in this process and release their substances such as growth factors which result in hyperplasia, lipid accumulation as well smooth muscle hyperplasia and smooth muscle migration and finally atheroma formation. These results were also obtained in animal experiments.

This view was followed by "Endothelial Dysfunction" by Gimbrone in 1980 and "hypo/dysfunction of EC with hyperactivity of platelets" by Ulutin in 1986, Depending on our observation we can say that Endothelial dysfunction could be of two types "EC dysfunction that exist genetically" or "EC becoming defective in acquired form"^[4,55,119, 133,262]. Endothelium has been recognized as one of the major contributors in initiation and progression of atherogenesis. We are not going to cover related literature extensively, since we already mentioned them in our earlier publications in detail. But I would like to summarize our observations in the cases of atherosclerosis from hemostasis standpoint^[1-4,27,45,46,59,68,127,130,164,165,195,201,217,272-274]. Also there are many books and reviews mentioning the historical and scientific developments of the subjects. I am citing some of them^[27,54,55,64,65,71,100,119,131,133,142,144,145,149,196,197,209-211].

First I would like to summarize what type of alterations take place in the hemostatic system in this group of cases:

- a. Hypo/Dys-function of EC,
- b. Decreased and altered fibrinolytic system

and its activity; with and without molecular alterations,

c. Increase of some coagulation factors, with and without molecular alterations,

d. Decrease of natural inhibitor activity with/without molecular abnormalities, in vascular system especially in haemostatic mechanism.

e. Hyperactivity of platelets with some functional and biochemical alterations.

f. The role of Monocytes.

A. The role of EC and its function in Hemostasis, Atherosclerosis and Thrombosis have been summarised extensively on the following publications [1,2,4,12, 27,55,59,68,74, 79,89,100,117,119,120,127,128,130-134,139,140,141, 150,164-166,168,194-196,200,203,206,209,217,221, 258] (Table 1). There is increasing evidence that the EC is involved in numerous physiological and pathological processes in the vascular system as well as in the haemostatic mechanism. Its inner surface with TF and its lipid composition and also phospholipid surface have important roles in the activation of hemostatic system. The EC has a strong antithrombotic function due to the substances that it contain and synthesizes. In atherosclerosis these functions and substances are reduced and altered (Table 2). The inner surface of EC has a proteoglycan layer that is a reason to be nonwettable^[64,68,119, 133,134,140,196]. Many proteoglycans such as heparan sulfate (HS), dermatan sulfate (DS) and heparin are synthesized in EC. In 1957 Ulutin and Fiestakof developed "Heparin Loading test" and showed, depending on this test there is a resistance to heparin in the cases of atherosclerosis and also in hypercoagulability^[4,136,137,156,224]. Karaca and Koşar confirmed these results in 1964^[216]. In 1964 Özdamar demonstrated that the cases of atherosclerosis had diminished amount of heparin and these patients also show a resistance to heparin^[2,214,215](Table 2). Depending on heparin loading test and its modification, it has been shown that resistance to heparin decreases during intermittent heparin therapy^[136,137,156,214,215]. LMW heparin was demonstrated in the heparin fractions in 1974 by Güven et al^[303,304]. Now we have many LMW hepa-

Table 1. Summary of the substances contained and produced by the endothelial cells related with haemostasis

- Increase of platelet adhesion with and without other platelet defect
- Alteration of foreign surface activation
- Hyperaggregation with aggregating agents
- Occasionally spontaneous platelet aggregation
- Hypersecretion
- Increase of platelet markers in plasma
- Increase of platelet alpha 2-Antiplasmin
- Decrease of platelet AT-III
- Decrease in gamma glutamyl transferase in platelets
- Increase in PGF2 alpha, PGE, MDA and TXA2
- Defective glucose membrane transport to the platelets and red blood cells
- Alteration of membrane phospholipids
- Increase of galactose transportation to the platelets and some alteration of membrane glucoproteins
- Shortening half life of the platelets
- In some cases an "Acquired storage pool deficiency of platelets" occur

rins with different molecular size and slightly different effects. We get similar results with LMW heparins as we showed above with UF heparins. Also LMW heparins show comparatively different effect for the management and therapy in vascular diseases^[115]. In the electrically induced thrombosis model LMW and HMW heparins shows different appearance in dogs^[254]. We demonstrated that in HMW heparin treated dogs, the larger mass of thrombus rich in red cells were seen. The EC was damaged. In LMW heparin treated dogs the EC was in normal appearance and keeping their unity and only some areas of tiny fibrin layer existed. With LMW heparin fibrinogen levels decrease. On the contrary with HMW heparin fibrinogen levels increased.

EC produces antithrombotic and prothrombotic substances as follows: Antithrombotics [HS, tissue plasminogen activator (t-PA), urokinase (UK), Thrombomodulin, Prostacyclin, nitric oxide (NO), 13-HODE, Protease Nexin, etc.] and prothrombotics [plasminogen activator inhibitor 1 (PAI 1), PAI 2, 15-HETE, von Willebrand factor (vWF), TT, Endothelin, platelet activating factor (PAF) etc.].

Tissue factor (TF) (Tissue Thromboplastin) is a low molecular weight integral membrane glycoprotein, few expressed in healthy endothelium, also located in the intima, and some in adventitia^[12,55,74,79,100,131,144,150, 164,194, 203,206,208,209]. TF is also located in within the platelets and leucocytes and especially monocytes. Besides EC,

Table 2. Plasma heparin levels in normal controls and in the cases of cerebroscerosis. Plasma heparin levels were determined using Engelberg's method (plasma heparin level mg/L). Data obtained from Özdamar's publication. Ref. No. 214-215

	PE	PS	PI	SPH	PC	Total p/10 PI
Atherosclerotics (n: 32)	4.32 +	0.95 +	0.76 +	2.87 +	5.86 +	14.76 + 1.2
Normals (n: 30)	2.98 +	0.53 +	0.37 +	2.06 +	4.1 +	10.04 + 1.05
Increase %	45	79	24	39	43	44

TF is also released from leucocytes, platelets and especially monocytes^[142,222,309]. TF content and its availability increases in the cases of atherosclerosis^[12,298]. As known TF and VIIa have a role in the activation of extrinsic system and also TF activates factor IX in the intrinsic system of coagulation mechanism^[206, 208]. TF expression increases in atherosclerosis with and without angina and myocard infarction. TF also releases from monocytes in the cases of hypercoagulability associated with angina and myocard infarction^[12,79,80, 100,119,120,142,165,166,222]. The procoagulant activity of EC increase after infection with some respiratory viruses or after arterial injury^[79,296]. Also some infection promote of development of atherosclerosis such as *Chlamydia pneumoniae*^[108]. TF is a lipoprotein and its molecular weight is approximately 45.000, TF is located on chromosome 1p 21-22. Recently it has been published that high level of adhesion molecules are measured in patients with peripheral arterial disease with impaired EC function^[139,150].

A substance produced by the EC named TF Pathway Inhibitor (TFPI) inhibits the action of TF, TF/VIIa and Xa, So coagulation mechanism is inhibited by TFPI in the early stage in the EC and its surface. It was difficult to demonstrate it with standard coagulation tests. This shows another observation about anticoagulant activity in test tubes there are different antithrombotic activity^[13-22,75,80,83,109,112,163,166,167,172, 181,264,286]. In blood, Lp(a) bounds TFPI and inactivates it approximately 60-70 percent.

Only free TFPI inhibits certain substance such as TF, TF/VIIa, Xa, elastase etc. In the cases of atherosclerosis Lp(a) levels increase so TFPI activity decreases^[63,68,161,163,171, 173,223]. In our patients with atherosclerosis Lp(a) was in normal control 29.3 + 25.01 mg/dL and in patients 97.89 + 77. 92 mg/dL and $p < 0.001$ (n: 100). Some drugs such as heparin, LMW heparin, defibrotide stimulate the production and release of TFPI^[17]. The potentiation of the effect of these drugs is, at least partially, due to increased level of TFPI. Recently it has been shown that a molecular abnormality exist in human TFPI in some cases of thromboembolism especially in the cases with venous thrombosis and also with acute coronary

syndrom^[13-23,75,80,83,109,112, 198].

Prostacyclin (PGI 2) and NO synthesized by the EC play an important role in the changes related to atherosclerosis. In atherosclerosis PGI 2 production and release decrease progressively. Prostacyclin is a very potent anti aggregator and vasodilator substance and stimulates the formation of c-AMP from ATP. PGI 2 decreases significantly in experimental and clinical atherosclerosis^[1-5,68,129, 193,278]. The decreased prostacyclin levels in atherosclerotics increases the platelet activation. PGI 2 also decrease in diabetes mellitus, smokers, hemolytic uremic syndrom, lupus anticoagulant, preeclampsia, vit E deficiency and neonatants. In our work we found Plasma 6-keto-PGF 1a levels for normal controls were 96.4 pg/mL and for atherosclerotics 37.7 pg/mL and the difference was $p < 0.001$ in our patients^[193].

EC also produces NO. NO is a vasodilator, decreases the tonus of smooth muscle and also inhibites aggregation and adhesion of platelets and also neutrophil adhesion, and inhibits VSMC proliferation. NO is produced in EC by NO synthase. PGI 2 and NO act synergistically^[194,196,220]. It has been shown that the level and production of NO decreases in atherosclerosis^[1-7,44,191,193]. The earliest endothelial dysfunction is reduced NO production. Akar et al demonstrated that a significant association exists between ccNOS polymorphism and cerebrovascular accident but not DVT in Turkish patients^[44]. Radomski et al showed that endogenous NO inhibits platelets adhesion to endothelium^[6]. NO also prevent restenosis after angioplasty^[7].

On the other-hand, in 1988 Yanasigawa et al isolatet a polypeptide from EC and named it as "endothelin"^[8,9]. Endothelin has a strong vasoconstrictor activity, increases the smooth muscle tonus in atherosclerosis, stimulates platelet and mitogen formations. PGI 2 and NO counteract to endothelin. In the case of atherosclerosis endothelin level is increased and also in ischemic heart disease and possibly in hypertension^[7-11,192,194,196]. Endothelin causes vena jugularis thrombosis in rabbits as well other animals experimentally^[11].

PAF is a 1-o-alkyl-2-acetyl-glycerol-3-phosphoril-choline produced by EC, neutrophils and macrophages and activates the platelets that causes aggregation and secretion. PAF stimulates platelets and facilitates the adherence of neutrophils to the EC by stimulating them. It has been demonstrated that stimulation of EC by thrombin, histamin, bradykinin, leukotriens etc increases the level of PAF.

This increase is more marked in the cases of atherosclerosis^[1,2,56]. Thus PAF is involved in vascular alterations and thrombosis formation and has a role in atherosclerotic change by producing platelet activation and endothelial injury^[160,229].

It was shown that the production of vWF increases in the cases of atherosclerosis so platelet adhesion increase. At the same time Fibrinogen and factor VIII also increase. Plasma concentration of vWF increase in acute myocard infarction^[93,199]. There are few, publications which mention a decrease of vWF in the EC^[117]. In atherosclerosis, EC function is altered so antithrombotic role of the EC decreases.

EC produce thrombomodulin. Thrombomodulin bound thrombin and inactivate it. This thrombin/thrombomodulin complex activate Protein C with a cofactor Protein S that inhibits FV and FVII. Thrombomodulin is in a way a natural anticoagulant on the surface of endothelium. Also binding of the thrombin in the injured area has some protecting role of microcirculation. In collagen vascular diseases the level of plasma thrombomodulin represent a marker of vascular injury^[257]. Gene polymorphism was demonstrated in a women with early onset preeclampsia^[85].

Using ELT and Fibrin plate methods we demonstrated that there was a clear difference between normal control and atherosclerotics (Table

3). The answer to Cuff test significantly decreases. t-PA, UK and PAI 1 are synthesized in EC. It also has been shown fibrinolytic activity decreases in the cases of atherosclerosis due to decrease of t-PA or increase of PAI-1 sometimes together^[69,81,232].

B. Fibrinolytic system activity shows different alterations in the cases of atherosclerosis with and without thrombus formation [1,2,4,25-27,69,81,82,84,89,92,95,97,113,157,163,177,193,200,232,299]. t-PA and PAI 1 synthesized in EC, in one sense control the fibrinolytic activity. There are many reports mentioning reduced fibrinolytic activity in atherosclerosis. The balance between PAI 1 and t-PA is important in the cases of atherosclerosis with/without thrombosis^[25,27]. Among 250 cases with atherosclerosis PAI 1 was excess in 207 cases and t-PA decreased in only 24 cases and no change in 19 cases. Also molecular abnormality has been described in PAI 1 and PAI 2. In a group of MI (n= 66) with healthy control (n= 20) a significant difference in PAI 2 was found^[42,43]. There are many studies showing the alteration of fibrinolytic system in the cases of atherosclerosis, myocardial infarction and thromboembolism with and without molecular defects^[42,43,82,84,89,92,97,105,113]. There are several studies showing the relation between fibrinolytic system and the development of atherosclerosis^[27]. There are many animal experiments showing the inhibition of fibrinolytic system cause atherosclerotic changes in vascular wall and promotes thrombus formation^[27,69,72]. On the other hand the activation of fibrinolytic system in animals prevents or decreases EC alteration as well decreased smooth muscle alteration. Berkarda demonstrated that dicoumarol and UF heparin when administrated in therapeutic doses inhibits euglobulin lysis time in 1962^[305].

Table 3. The results of ELT and Fibrin plate in normals and atherosclerotics

	Normal control (n: 80)	Atherosclerosis (n: 80)
VIIIc	96 + 16	178 + 64
VIII Ag (vWF)	103 + 22	162 + 43
VIII Ri-co F	592 + 23	159 + 39

C. In the cases of atherosclerosis with and without thrombosis some coagulation factor levels increase and circulate in activated forms and cause hypercoagulability. We can measure their plasma levels immunologically or their procoagulant activity or their activation peptides. In atherosclerosis some factors increase such as Fibrinogen, FVIII, vWF, XII, IX, X, VII, V etc. In this group of cases prothrombin fragments 1 + 2 and "Activation peptide"s of IXa, Xa, XIIa increase^[2,32,122].

And also some coagulation factors show molecular alterations^[73,116,135,141,143,207,226].

Another vitamin K dependent, calcium ion binding protein is Protein Z^[106,213,240]. Molecular weight is 62.000 D, like Protein C, and half life is 2.5 days. Although Protein Z sequence is homolog with IX, Protein C and other serin protease did not show a serine protease activity due to absence of active center aminoacid sequence. In the presence of Protein Z, thrombin bound to phospholipid surface. Protein Z, deficiency causes bleeding tendency. 60% of unexplained mild bleeding tendency might be related to low level of Protein Z as well some thrombus formation^[213,241,242]. Protein Z has an important function in maintaining hemostasis and also has a role in the pathogenesis of thromboembolism. On the other hand the presence of Protein Z on macrovascular EC in atherosclerotic lesions has been demonstrated. It seems that Protein Z is also a marker for proliferating activity of the vessel wall.

We observed in our laboratory all vitamin K depended coagulation factors deficiency including prothrombin, factor VII, factor IX, factor X, Protein C, Protein S and also deficiency of fibrinogen, factor V, factor VIII, factor XI, factor XII and vWF etc (Table 4).

Factor VII/VIIa and TF/VIIa has important role in the activation of blood coagulation. They activate extrinsic coagulation mechanism and also through the activation of factor IX effect also the intrinsic system. TFPI inhibits this activation.

Factor VII congenital deficiency causes a bleeding tendency and this clinically resembles a platelet disorder. First congenital factor VII deficiency was published in Turkey in 1958 and follo-

wed with others^[122,187,292]. Factor VII is a glycoprotein, a single chain with 405 aminoacid and molecular weight is 50.000. Factor VIIa make a complex with TF and activate factor X and factor IX. This interaction increase the catalytic activity of serine protease. Factor VII has many mutations. The clinical symptoms and factor VII activity demonstrated poor correlation^[122,186,208]. Recently recombinant VIIa is used in the treatment of the bleeding of severe thrombocytopathia^[121,295]. Also rVIIa is used in the Hemophilia A cases with inhibitor succesfully^[263,296].

We also have congenital hypoprothrombinemia (Factor II deficiency)^[293].

Fibrinogen levels increase significantly in the cases of atherosclerosis with and without thrombosis. A significantly high fibrinogen polymerization curve occurs. Fibrinogen became more sensitive to thrombin compared with normal control.

The clot is comparatively resistant to fibrinolytic substances. This may be related to their content of HMW fibrinogen (Table 5). Also HMW fibrinogen ratio increases in the fibrinogen of patients with atherosclerosis and they have higher risk of thrombosis^[28-30,57,99,123]. Also fibrinogen anomaly was shown in the cases of myocard infarction^[57]. In this group of cases vWF also increases significantly^[197]. From laboratory findings, this type of cases show some similarity with chronic lowgrade DIC^[24] (Table 6).

On the other hand, many recent publication indicate high levels of factor VIII is a risk factor of venous thrombosis as well arterial thrombosis. As we mentioned in our earlier publications, fibrinogen level increased significantly in atherosclerosis, in stroke and in- POAD^[32,33,93,117,197,225]. The increased levels of D-Dimer and FPA are the indicators of intravascular coagulation. The recognition of specialized membrane receptors and binding of fibrinogen to leucocytes as well as regulation of leucocytes-endothelium interaction by fibrinogen give an additional regulative role to the fibrinogen^[28-33,57]. The half-lives of fibrinogen and platelets are decreased in the cases of atherosclerosis^[123].

We demonstrated that in leukocyte cultures a

Table 4. The distribution of factor deficiency among 327 patients registered in our division between 1960-1985 (294)

ELT (Min)			
Control (n: 42)	97 + 21	41 + 19	56
Patient (n: 41)	153 + 37	134 + 38	19
F ₁ BR ₁ N PLATE			
Control (n: 42)	43.6 + 9.5	93.2 + 16.4	49.6
Patient	26.8 + 11.4	47.2 + 16.6	20.4

substance with factor VIII-like activity synthesise in normal healthy donors but not in Hodgkin's^[266].

In 1965 and 1967 blood samples taken from coronary sinus by cardiac catheterization, brachial artery and vein were compared from coagulation activity between normal controls and atherosclerotics^[276,290,310]. In normal control the coagulation activity between samples showed clear difference and arterial blood showed higher activity than venous blood drawn from coronary sinus. Blood passing the normal myocardium loses some its activity. In normal myocardium it has a regulative role. In atherosclerosis there is no difference between samples, so myocardium loses this regulative role in the cases of atherosclerosis. This difference is also clearly demonstrated using thromboelastography.

D. Decrease of natural inhibitors activities with/without molecular abnormalities were seen. In the cases of atherosclerosis, there is a resistance to heparin. The level of heparin decreases. We already demonstrated this using heparin loading tests^[136,137]. Heparin is produced by basophils, mast cells and EC and also EC produces HS. The surface of EC covered by HS has a role in nonwettable surface of EC with PGI₂.

As we will discuss later heparin produced by

EC has an inhibitory effect on platelet derived growth factor's effect on smooth muscle. Heparin's antithrombotic effect enhances through the activation of AT-III. AT-III and activated AT-III by UF heparin inactivate dose dependently XIa, Xa, VIIa and thrombin. On the other hand, by description, LMW heparin acts through on Xa. But in practice LMW heparin also acts through AT-III but in lesser degree and this is different from one product to other. We can say that LMW heparins are a group of similar proteoglycans but different drugs due to their activities. Heparins obtained from different tissues and different species also show some differences structurally^[1,4,34,35,104,115,172, 214-216].

We found that Protein C and S slightly decreases in the cases of atherosclerosis probably due to consumption.

In new born babies some vitamin K dependent factors are in low levels and this is more marked in premature babies but also observed in term. After vitamin K application the majority turn to normal levels. In some low levels persisted for a long time even months up to 6 months even more. This may cause wrong diagnosis^[13,73,109,178,230,282-284,301,302]. There are also publications, related with new born thrombosis and haemorrhage with different ca-

Table 5. Fibrinogen levels of normal controls and atherosclerosis

Marker	Control (n: 100)	Atherosclerosis (n: 100)	
PF-4 (IU/mL)	4.4 + 1.4	21.8 + 8.4	p< 0.001
β-TG (IU/mL)	16.1 + 9.3	82.1 + 21.6	p< 0.001

Table 6. von Willebrand factor levels in normal control and atherosclerotics

	Normal control (n: 260)	Atherosclerosis (n: 260)
Fibrinogen (mg%)	207 + 32	363 + 57
	p < 0.001	

uses^[35,73,138,178,185, 190,282,284,302].

Molecular alterations and/or polymorphism are demonstrated in the cases of thromboembolism and vascular disorders in Turkey as well in the literature^[23,31,36-44,54,58,76,78,82,84,85,87,89,91,92,95-98,110,111,113,114,151,165,173-176,179,182-184,188,189,191,198,202,207,226,230, 231,233]. Among these Leiden anomaly, PT 21020, methylenetetrahydrofolate, NO synthase, angiotension converting enzyme (ACE) gene variants, PAI 2 genetic distribution etc. In 1997 Özbek and Tangün mentioned the existence of FV Leiden in Turkish population^[37]. According to Akar et al in the cases of MI, CV infarct and DVT, Leiden anomaly was 25% and PT 21020 9%^[38]. Gürgey et al showed that 55 out of 142 adult cases with cerebral thrombosis, pulmonary thrombo-embolism, mesenterium thrombosis and DVT had molecular abnormalities such as 35 heterozygous factor V Leiden (24.6%) 6 homozygote cases (4.2%); 9 cases of PT 20210 (6.3%), 5 cases of combined defect of FV Leiden and PT20210A (3.5%)^[39]. Gürgey also demonstrated in Azerbaijan 43 healthy cases (18 heterozygote and 1 homozygote) with methylenetetrahydrofolate reductase C677T mutation (MTHFR C667T) and also 6 cases with FV Leiden. These cases were chosen from the general population and had no history of thrombosis^[40].

Akar et al demonstrated endothelial NO synthase polymorphism in a Turkish patient with DVT and cerebrovascular accident^[41,44]. In another study, Sayhan et al showed a significant difference observed in the cases of MI comparing with normal healthy people and also a deletion of polymorphism in gene encoding ACE gene variants in patients with MI and normal control existed in certain percentage and also significantly different PAI

2 genotype distribution between MI and control group^[42,43]. Also deletion polymorphism at the converting enzyme gene in patient with coronary artery disease, PAOD, and carotide atherosclerosis is published^[42,43,84, 173, 204] (Table 7).

In another study made in our clinic 35 patients with thromboembolism had 8 Protein S deficiency, 7 APC-resistance, 4 antiphospholipid antibody syndrome, 3 Protein C deficiency and 2 AT-III deficiency^[58]. We also presented a family with 2 cases of homozygote AT-III deficiency. Father and mother were relative and in the family there was 4 heterozygous AT-III deficiency^[35]. Recently Akar published the results of pediatric cases with molecular alteration with thrombosis in detail^[226]. In some cases of thrombosis a mutation of Protein C gene was demonstrated^[114,285].

Some molecular abnormality was observed in some of the cases of Buerger disease causing a risk factor for thromboembolism^[135]. Among prothrombotic mutations of prothrombin 20210 G-A is higher than others in Buerger diseases. This combination aggravates vascular pathology and possible thrombus formation. Certainly this observation needs further studies.

Vascular alterations, EC dysfunction, thrombus formation and alteration in the haemostatic system are among the findings in the disease originally described by Hulusi Behçet in 1937 as a dermatologic disorder^[259]. There are some publication related with the alteration of EC function as well hemostatic system in Behçet's disease^[60,129,219,251-256].

Thrombosis and hemostasis in antiphospholipid syndrome^[90,102,212,261]: Under this title, there are different clinical and laboratory entities such as Lupus anticoagulant, anticardiolipin antibodies, etc. With these antibodies arterial and venous system thrombotic events occur such as cerebrovascular thrombosis, transient cerebral ischaemic attacks, coronary artery thrombosis, retinal thrombosis, venous thrombosis etc. All are acquired phenomena.

E. In Table 8 the alteration of platelet function and biochemistry is summarized. The subject of platelet release mechanism has been introduced

ced to the literature in 1956 by Ulutin and Karaca[45,46,124,159,237-239,270,277]. It has been demonstrated by various methods that platelet adhesion, aggregation and secretion increase in atherosclerotic subjects[45,275]. The increase in the platelet adhesiveness and aggregation were more pronounced in the prethrombotic stage and during transient ischaemic attacks. The alterations of platelet in the cases of atherosclerosis with and without thrombosis are as follows: Hyperaggregation, hypersecretion, hyperadhesion and mitogen formation and release[45-47,59,67,70,130,234]. The alteration of platelets was observed during different osmotic resistance tests[236-239,275,277,306].

Platelets do not adhere to normal endothelium but to injured EC and to subendothelium. Platelets also adhere to functionally altered EC. The continuity of heparan sulfate layer on the surface of EC decreases and also PGI 2 formation of EC decrease so more platelets adhere to the EC surface.

Using platelet retention test, it was shown that, more platelets adhere to the foreign surface.

Using Rebeck technique, we measured the differential counts of platelets on formvar membrane using shadow-casting technique of electron microscope[2,4,45-47]. In normals the majority of platelets were in dendritic form 66% and per hundred single platelets only 4.5% small aggregates observed. On the other hand, in the cases of atherosclerosis 12.6% small aggregates and 5.2% gross aggregates existed (Table 9). This is also shown by Marion Barnhart and her group in the cases of transient ischaemia and cerebrovascular disorders[48]. Certain antiaggregating drugs like aspirin normalize this pathologic alteration. Our results of functional and biochemical alterations of platelets from atherosclerotic patients are

summarized in Table 8. And also using thin section methods of electronmicroscopy the ultrastructural alterations were of platelets were shown in normals, in pathologic conditions as well under certain drugs[234,277,281]. When platelets adhere to subendothelium they release growth factors including β -TG, chemotactic substances, antiheparin (PF-4) and also procoagulants (PF-3) which gives them a role in the pathogenesis of atherosclerosis. In the cases of atherosclerosis, main functions of platelets significantly increase[45,46]. This is observed in congenital or acquired form of atherosclerosis. Mammen described a congenital form and named it as "Sticky Platelet syndrome"[49,50]. Increased spontaneous platelet aggration is a risk factor in the thromboembolic complications in vascular disorders[280]. Platelet shows hyperaggregation to the aggregating agents such as adrenalin, ADP, collagen etc. Platelet secretion due to induction increases significantly in the majority of platelets. In some cases platelets already release their materials before the induction with aggregating agents and in these cases platelets circulate as ghost forms[24]. Among secreted and released factors PF-3 is a procoagulant, PF-4 is an antiheparin factor, Smooth muscle proliferative factor is a mitogen factor, and β -TG is also a mitogen factor. We showed that there is excessive secretion by measuring ADP, PF-4, β -TG, Platelet Fibrinogen, Platelet alpha-2-antiplasmin etc[45,270,279] (Table 10). Alteration of platelet membrane phospholipids distribution in atherosclerosis was shown[45,51,158,300]. The total amount of membrane phospholipids was increased, but each phospholipid is increased in different rate. Also different results obtained with different release inducers (Table 11).

Some alterations and amount in the substan-

Table 7. ACE patients with MI & controls. ACE gene variants (42,43)

Control in rest (n: 30)	1.42 + 0.38	TXB ₂ (P mol/mL)
Atherosclerosis (n: 62) in rest	2.84 + 1.76	TXB ₂ (P mol/mL)
After effort angina or Trait-Mill (n: 60)	7.32 + 2.63	TXB ₂ (P mol/mL)

Table 8. Functional and biochemical alteration of platelets in the cases of atherosclerosis

	Aggregation per 100 single platelets					
	R	D	I	S	Small	Gross
Normal (n: 22) %	3.2	66.4	20	10.3	4.5	-
Other (n: 23) %	2.1	24.6	25.1	47.4	12.6	5.2
T-test	p= 0.01	p< 0.001	ns	p< 0.001	p< 0.001	

ces stored in granules of platelets have been demonstrated in these group of cases. It has been shown that the level of platelet AT-III, which is stored in platelet granule and is secreted after induction, is lower in the cases atherosclerosis[1,2,4,227,228,235]. In the cases of atherosclerosis, platelet AT-III and cAMP levels were decreased significantly. The decrease of cAMP in unactivated platelets indicate that platelets were already activated in resting condition. So acquired storage pool deficiency occur like chronic low grade DIC[24].

On the otherhand, platelet a2-antiplasmin increases. Together with the alteration of t-PA and PAI 1 resulted a decrease of global fibrinolytic activity in the cases of atherosclerosis. We may also add alteration of PAI 2 in the cases of MI[1,2,4,27,45,46,124,125].

As we demonstrated in 1985, the synthesis of PGF 2a, PGE 2, MDA, and TXA 2, are increased in atherosclerosis compared to normal after induction with collagen and ADP. At the same time platelet cAMP level decreases[1-5,45,46,169,271]. The importance of eicosanoid metabolism on EC

and on platelets is recognized (Table 11).

We demonstrated that the active transport of ¹⁴C glucose to the platelet and red cell is defective in the cases of atherosclerosis; both diabetic and nondiabetic patients. In the platelets of normal subjects, ¹⁴C-glucose is transported across the membrane both by simple diffusion and active energy dependent mechanisms. The specific glucose binding protein is absent or decreased significantly or molecularly altered in the platelet cell membrane of atherosclerotics[1-4,46,52,59,67,128,130,236]. On the otherhand juvenil diabetic patients does not exhibit this defect.

¹⁴C glucose normally binds to the protein peak when osmotic shock is done then supernatant is fractioned by chromatography, but it does not bind to a protein and stays as free glucose in atherosclerotic cases with impaired transport.

And also in our laboratory, was studied on the platelet membrane transport of Arachidonic acid, Leucin transport aminoacids transport palmitic acid transport in normal and patients and also the effectsof certain drugs on membrane transport system[244, 245,267-269,281].

Table 9. Differential count of platelets from normal control and atherosclerotics on formvar membrane using electron microscope with shadowcasting technic

	Parents	Young member	Young control
Defective cuff test (%)	82.6	43.7	11.6
Decreased prostacyclin (%)	72.8	31.9	9.8
Hyperadhesion, hyperaggregation and hypersecretion of platelets (%)	85.2	22.4	8.3
Glucose transport defect (%)	84.2	32.3	4.5
Increase of β -TG, PF-4	89.9	16.7	5.2

Membrane transport is also found defective in the red cell membrane in the cases of atherosclerosis and diabetes mellitus^[107,168, 201]. Some drugs such as defibrotide, metformin, gliclazide partially correct this defect and impaired mechanisms. Insulin receptors also decreases in the case of atherosclerosis with or without diabetes mellitus^[203-205] (Table 12).

The membrane transport system of Red cell shows some similarity to platelets in normal and pathologic conditions^[107,168,201, 248,289].

We also demonstrated that g-glutamyl transferase activity was $50.78 + 3.37 \mu/10^8$ Platelet for normal control but platelets obtained from atherosclerotic subject g-GT activity decreased to $24.78 + 3.98 \mu/10^8$ platelets on the other hand there was no in difference glutathion levels^[53,62,249].

Platelets obtained from atherosclerotic patient produce more lactate and also platelets of atherosclerotic patients contained less glycogen^[155,250].

It also shows that galactose transport to the platelet is normal but the incorporation of galactose to the platelets increases protein and this may explain the changes of pattern of membrane glycoprotein in atherosclerosis^[66,243,246].

Some of the defects presented above are also found in the young members of atherosclerotic families. Both parents and families had atherosclerotic disease with thrombotic complications such as MI, stroke, POAD etc. Young members of these families had normal fundus oculy, normal levels of serum lipids with normal distributions, and

no hypertension. Some of the haemostatic tests showed some abnormalities such as Cuff test, prostacyclin levels, higher aggregation curves, increase of platelet markers and defective glucose transport compared to the control of same age^[52,53]. The preliminary studies suggest that the primary alteration is impairment of function of the EC followed by platelet dysfunction in these young members between ages 8 to 18 (Table 13).

We are not going to discuss and summarize, the alteration of leucocytes, smooth muscle cells and others in detail in this short review that mainly depends on ours and collaborators results. They already have been partly discussed and published in our earlier publications [3, 4, 6, 9, 11, 25, 27, 43, 45, 46, 51, 52, 59, 67, 70, 77, 127, 158, 162, 163, 168, 169, 193, 200, 236, 244, 249, 250, 270, 277, 279, 281].

It is not possible to cover every part of the subject even all our work has been done during the last 50 years on the topic related with hemostasis, thrombosis and atherosclerosis. Coagulation, fibrinolysis, platelets, natural inhibitors and haemorrhagic disorders is not covered in this superficial review.

REFERENCES

1. Ulutin ON. Hemostasis and atherosclerosis. In: Leon Poller (ed). Recent Advances in Blood Coagulation 5. Edinburgh: Churchill Livingstone, 1991;5:53-78.
2. Ulutin ON. Haemostasis and atherosclerosis. In: Neri Serneri GG, Gensini GF, Abbate R, Prisco D (eds). Thrombosis an Update. Florence: Scientific Press, 1992:61-77.

Table 10. PF-4 and β -TG levels in normal control and in atherosclerosis

Group	Receptor no	Insulin bound %	Glucose exchange rate (n.mol/mL cell/min.)
Control n: 20	477.10 + 56.46	11.00 + 0.94	1.01 + 0.02
Athero. n: 20	231.10 + 49.77	8.15 + 1.05	0.35 + 0.08
NIDDM n: 15	186.90 + 18.50	4.50 + 1.8	0.65 + 0.09

Table 11. The alteration of platelet membrane phospholids in normal subjects and in the cases of atherosclerosis

VIII deficiency	62.5%
von Willebrand disease	16.5%
IX deficiency	11.0%
V deficiency	11.0%
VWD + thrombopathia	1.5%
VII deficiency	1.5%
II deficiency	0.9%
VII and IX deficiency	0.6%
XIII deficiency	0.6%
I deficiency	0.6%
XII deficiency	0.3%
VWD + thrombasthenia	0.3%
Angiohaemophilia	0.3%
Dysfibrinogenemia	0.6%

3. Ulutin ON, Çizmeçi G. Alteration of prostanoids in atherosclerosis. *Semin Thromb Hemost* 1985;11: 362-8.
4. Ulutin ON. Atherosclerosis and hemostasis. *Semin Thromb Hemost* 1986;12:156-74.
5. Dembinska-Kiec A, Grygowski RJ. Contribution of arachidonic acid metabolites to atherosclerosis. *Wien Klin Wochenschr* 1986;98:197-206.
6. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric acid inhibits human platelets adhesion to vascular-endothelium. *Lancet* 1988;2:1057-8.
7. Loscalzo J. Nitric oxide and restenosis. *Clin Appl Thrombosis/Hemostasis* 1996;2:7-13.
8. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y,

- Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produce by vascular endothelial cells. *Nature* 1988; 332:411-5.
9. Takuwa Y, Yanagisawa N, Masaki T. Endothelin, its divers biological activities and mechanisms of action. *Prog Growth Factor Res* 1989;1:1905-206.
10. Thiermermann C, May G, Page C, Vane J. Endothelin-1 inhibits platelet aggregation in vivo: A study with Indium-labeled platelets. *Brit J Pharmacol* 1990;99:303-8.
11. Ulutin T, Bayram Ç, Okar I, Özlük K, Tözün N, Ulutin ON. The effect of endothelin 1 on vena jugularis thrombus model in rabbits. *J Basic Clinical Physiol Pharmacol* 1995;6:295-302.
- 12- Taubman MB, Giesen LA, Schechter AD, Nemerson Y. Regulation of the procoagulant response to arterial injury. *Thromb Haemost* 1999;82:801-5.
13. Altinkaya N, Uras F, Çetin E, Ersoy Ş, Uras AR, Ulutin ON. Plasma tissue factor pathway inhibitor in newborns and infants. *Haemostasis* 1998;28:357.
14. Ulutin T, Bayram Ç, Bolat F, Domaniç N. Tissue factor pathway inhibitor in patients with coronary heart disease. *Haemostasis* 1998;28:395.
15. Soejima H, Ogawa H, Yasue H, Nishiyama K, Kikita K, Misumi K, Takazoe K, Kugiyama K, Tsuji I, Kumeda K, Nakamura S. Plasma tissue factor inhibitor and tissue factor antijen levels after administration of heparin in patient with angina pectoris. *Thromb Res* 1999;93:17-25.
16. Sandset PM. The role of tissue pathway inhibitor as a physiological anticoagulant. In: Ulutin ON (ed). *Lectures; XIIIth Meeting of ISH (European-African Division) İstanbul: Meta Printing House, 1995:183-9.*
17. Balkuv Ulutin Ş, Ulutin ON, Walenga J, Hoppenstead D, Fareed J. Defibrotide mediated anti-Xa release and heparin synergism is mediated through tissue factor pathway inhibitor (TFPI). *International Angiology* 1995;14(Suppl 1):280.
18. Iverson N, Abilgaard U. Role of antithrombin and

Table 12. Red blood cell insulin receptors and glucose exchange rates. In normal controls, in the cases of atherosclerosis and in the cases of NIDDM

ACE genotypes	Patients (n: 66)	Controls (n: 22)
DD	20 (36.3%)	12 (60%)
ID	29 (49.9%)	7 (35%)
II	13 (19.6%)	1(5%)
D	0.583	0.775
I	0.417	0.225

Table 13. Some observations in the young members of atherosclerotics families

	Nonatherosclerotics	Atherosclerotics	
Endogen heparin level	1.64 mg	1.28 mg	p< 0.01
Postheparin (1 mg/kg)	7.97 mg	1.26 mg	p< 0.001

- tissue factor pathway inhibitor in the control of thrombosis and mediation of heparin action. *Clin Appl Thrombosis/Hemostasis* 1996;2:1-6.
19. Kleesink K, Schmidt M, Götting C, Brinkman T, Prohaska W. A first mutation in the human tissue factor pathway inhibitor gene encoding (P151L). *Blood* 1998;39:76-80.
 20. Soejima H, Ogawa H, Yasue H, Nishiyama K, Kikita K, Misumi K, Takazoe K, Kugiyama K, Tsuji I, Kumeda K, Nakamura S. Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris. *Thromb Res* 1999;93:17-25.
 21. Llobet D, Falcon L, Mateo J, Vallvé C, Martinez E, Fontcunerta J, Borrel M. Low levels of tissue factor pathway inhibitor (TFPI) in two out three members of a family with thrombophilia. *Thromb Res* 1995;80:413-8.
 22. Ariens RAS, Alberio G, Moia N, Mannucci PM. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. *Thromb Haemost* 1999;81:203-7.
 23. Bertina RM. Molecular risk factors for thrombosis. *Thromb Haemost* 1999;82:601-9.
 24. Ulutin OU, Ulutin ŞB. Acquired storage pool deficiency of platelets in chronic disseminated intravascular coagulation. In: Ulutin ON, Verrier Jones J (eds). *Platelets: Recent Advances in Basic Research and Clinical Aspects*. Amsterdam: Excerpta Medica, 1975: 282-91
 25. Balkuv Ulutin Ş. Homeostatic regulation of fibrinolysis by liver. *J Clin Pathol* 1972;619-20.
 26. Balkuv Ulutin Ş. Physiological response to enhanced fibrinolytic activity. In: Gaffney PJ, Balkuv Ulutin Ş (eds). *Fibrinolysis: Current Fundamental and Clinical Concepts*. London: Academic Press, 1978:27-36.
 27. Balkuv Ulutin Ş. Fibrinolytic system in atherosclerosis. *Semin Thromb Hemost* 1986;12:91-101.
 28. Henschen Edman AH. Molecular basis of normal and abnormal fibrinogen. In: Ulutin ON (ed). *Lectures, XIIIth Meeting ISH-European & African Div Istanbul*: Meta Printing House, 1995:153-6.
 29. Henschen Edman AH. Identifying the beneficial and the detrimental properties of fibrinogen. *Lectures: 15th International Congress on Thrombosis*. In: Ulutin ON (ed). *Istanbul: META Printing and Publishing House, 1998:68-72.*
 30. Altirei DC. Regulation of leukocytes-endothelium interaction by fibrinogen. *Thromb Haemost* 1999;82: 781-6.
 31. Samama MM, Gerrotziafas G, Conard J, Horellou MH Elalamy. Clinical aspects and laboratory problems in hereditary thrombophilia. *Lectures: 15th International Congress on Thrombosis*. In: Ulutin ON (ed). *Istanbul: Meta Printing and Publishing House, 1998:7-23.*
 32. Rosendaal FR. High levels of factor VIII and venous thrombosis. *Thromb Haemost* 2000;583:1-2.
 33. Kraaijenhagen RA, in'Anker PS, Koopman MMW, Reitsma PH, Prins MH. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. *Thromb Haemost* 2000;85:5-9.
 34. Vinazzer H. Hereditary and acquired antithrombin deficiency. *Semin Thromb Hemost* 1999;25:257-63.
 35. Haktan M, Deniz U, Özbay G, Ulutin ON. Two cases of homozygous antithrombin III deficiency in a family with congenital deficiency of AT-III. In: Sinsinger H, Vinazzer H (eds). *Thrombosis and Hemorrhagic Disorders*. Würzburg: Schmitt & Meyer, 1989: 177-81.
 36. Dahlback B. Activated protein C resistance and thrombosis; molecular mechanisms of hypercoagulable state due to FVR506Q mutation. *Semin Thromb Hemost* 1999;25:273-89.
 37. Özbek U, Tangün Y. Frequency of factor V Leiden (Arg 506 Gln) in Turkey. *Brit J Haemat* 1997; 97:504-5.
 38. Akar N, Akar E, Dalgın G, Sözüöz A, Ömürlü K, Cin Ş. Frequency of factor V (1691 G-A) mutation in Turkish population. *Thromb Haemost* 1997;78: 1527-8.
 39. Gürgey A, Mesci L. The prevalence of factor V Leiden (1691 G-A) mutation in Turkey. *Turk J Pediatr* 1997;39:313-5.
 40. Gürgey A, Rüstemoğlu R, Parlak Balta G. Prevalance of factor V Leiden and Methylene tetrahydrofolate reductase C677T mutation in Azerbaijan. *Thromb Hemost* 1998;80:520-1.
 41. Akar N, Aras Ö, Ömürlü K, Cin Ş. Deletion polymorphism at the angiotensinogen converting enzyme gene in Turkish patients with coronary artery disease and controls. *Scand J Clin Lab Invest* 1998; 58:491-5.
 42. Sayhan N, Gürel ÇB, Yılmaz Ş, Ulutin T. ACE gene

- polymorphism and PAI 2 variants in myocardial infarction. XVth Meeting of ISH-EA Div, 1999 Sept 18-23, Durban, SA. HT 8.
43. Sayhan N, Bayram Gürel Ç, Yılmaz Ş, Ulutin T, Ulutin ON. PCR-RFLP detection of PAI-2 gene variants and gene polymorphism in myocardial infarction. *Haemostasis* 2000;30(Suppl 1):140.
 44. Akar A, Akar E, Cin Ş, Deda G, Avcu F, Yalçın A. Endothelial nitric oxide synthase intron 4.27 bp repeat polymorphism in Turkish patients with deep vein thrombosis and cerebrovascular accidents. *Thromb Res* 1999;94:63-4.
 45. Ulutin ON. The platelets: Fundamentals and clinical applications. İstanbul: Kağıt ve Basım İşleri AŞ, 1976:1-344.
 46. Ulutin ON. Functional and biochemical alteration of platelets in atherosclerosis and thromboembolism. In: Davidson JF, Cepelak V, Samama MM, Desyoner PC (eds). *Progress in Ohemical Fibrinolysis and Thrombolysis IV*. Edinburgh: Churchill Livingstone, 1979;4:260-5.
 47. Rebuck JW, Riddle JM, Brown MG, Johnson SA, Monto RW. Volumetric and ultrastructural studies of abnormal platelets. In: SA Johnson RW, Monto JW, Rebuck RJ Horn Little (eds). *Blood Platelets*. Boston: Brown & Co, 1961:533-52.
 48. Walsh RT, Bauer RB, Barnhart MI. Platelet function in transient ischaemia and cerebrovascular disease: Effect of aspirin and contrast media. In: Ulutin ON (ed). *Platelets: Recent Advances in Basic Research and Clinical Aspects*. Amsterdam: Excerpta Medica, 1975:367-77.
 49. Mammen EF, Barnhard MI, Selik NR. Sticky platelet syndrome: A congenital platelet abnormality predisposing to thrombosis. *Folia Haematol (Leipzig)* 1988;115:361-5.
 50. Mammen EF. Sticky platelet syndrome. *Semin Thromb Hemost* 1999;25:361-5.
 51. Aktulga AZ, Ulutin ON. Platelet phospholipids in atherosclerotics and in normal before after release. In: GG Neri Serneri CRM (eds). *Haemostasis and Thrombosis*. London: Prentice Academic Press Ltd, 1979:677-83.
 52. Yardımcı T, Ulutin ON. Alteration of platelet glucose transport system in atherosclerosis. *Wiener Klin Wschr* 1986;98:221-2.
 53. Yardımcı T, Yaman A, Ulutin ON. The characterisation of platelet gamma-glutamyl transferase in the cases of atherosclerosis. *Clinical and Applied Thrombosis/Hemostasis* 1995;1:103-13.
 54. Bertina M. Molecular risk factors for thrombosis. *Thromb Haemost* 1999;82:601-9.
 55. Gimbrone MA Jr. Endothelial dysfunction, hemodynamic forces, and atherosclerosis. *Thromb Haemost* 1999;82:722-6.
 56. Whatley RE, Zimmerman GA, Mc Intyre TM, Taylor A, Prescott SM. Productions of platelet activating factor by endothelial cells. *Seminars Thromb Haemost* 1987;13:445-53.
 57. Haglund AC, Ronquist G, Frithz G, Ek P. Alteration of the fibrinogen molecule and its phosphorylation state in myocardial infarction patients undergoing thrombolytic treatment. *Thromb Res* 2000;98:147-56.
 58. Öngören S, Baslar Z, Aykut A, Köroğlu A, Ulutin O, Ferhanoğlu B. Risk factor evaluation of a cohort of patients suffering thromboembolic events. *Haemostasis* 2000;30(Suppl 1):132.
 59. Ulutin ON, Yardımcı T, Çizmeci G, Emekli N, Bal kuv Ulutin Ş. Some observations on the alteration of hemostatic mechanism in atherosclerosis and its pathogenetic relation to the disease. In: Ulutin ON, Vinazzer H (eds). *Thrombosis and Hemorrhagic Diseases*. İstanbul: Gözlem Printing & Publishing Co, Turkey 1985:1-4.
 60. Müftüoğlu AÜ. Thrombo-occlusive phenomena in Behçet's disease. In: Ulutin ON, Vinazzer H (eds). *Thrombosis and Hemorrhagic Diseases*. İstanbul: Gözlem Printing & Publishing Co, Turkey 1985:48-54.
 61. Ulutin T, Üçışık N, Bayram Ç, Sönmez H, Suer S, Kökoğlu E, Sultuğbek G. Ulutin ON. The molecular markers of hemostatic activation in coronary artery disease. *Haemostasis* 1996;26(Suppl 23):349.
 62. Yaman A, Yardımcı T, Ulutin ON. GGT (Gamma-glutamyl transferase), glutathione, lipid peroxidation, cholesterol and HDL-cholesterol levels in platelets of normal and atherosclerotic subjects. *J Pharm Univ Marmara* 1995;11:249-56.
 63. Sönmez H, Suer S, Kökoğlu E, Dirican A, Ulutin T, Üçışık N, Ulutin ON. The importance of Lp (a)-fibrinogen interaction in atherosclerosis. *Haematologia* 1997;28:149-53.
 64. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. *N Engl J Med* 1999;340:1555-64.
 65. Ross R. Atherosclerosis-an inflammatory disease. *N Engl J Med* 1999;340:116-26.
 66. Emekli NB. Galactose transport and glycoprotein changes in the platelets of atherosclerotics. In: Ulutin ON, Berkarda B (eds). *1981 International İstanbul Symposium on Haematology*. Kırklareli: Sermet Printing Co, 1981:89-101.
 67. Ulutin ON. Some observations on the alteration of the coagulation mechanism and platelet functions in atherosclerosis. *The Journal of Tokyo Medical College* 1980;38:151-9.
 68. Ulutin ON. Atherosclerosis, haemostasis and thrombosis. State of Art Lectures, 69-73 16th Congress on Thrombosis, May 5-8, Porto, Portugal.

69. Ulutin ŞB, Ulutin ON. Los cambios de la actividad Ofibrinolítica en las aterosclerosis Y en las condiciones tromboembolicas. I. Congreso Mediterraneo sobre Tromboembolias Bilbao, 1969:37-40.
70. Ulutin ON, Ulutin ŞB. El efecto in vivo e in vitro de algunas drogas sobre la agregabilidad Y adhesión plaquetaria en los sujetos normales Y en los ateroscleróticos. I. Congreso Mediterraneo sobre Tromboembolias, Bilbao 1969:45-8.
71. Duguid JB. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. *J Path Bacteriol* 1946;58:2087.
72. Hoşgör İ, Yılmaz S, Girişgen G, Şatroğlu G, Karadayı N, Balkuv Ulutin Ş. The morphological alteration of myocardial coronary vessels after the application of tranexamic acid in cats. In: Sinzinger H, Vinazzer H (eds). *Thrombosis and Haemorrhagic Disorders*. Würzburg: Schmitt & Meyer GmbH, 1989: 462-7.
73. Larsen TB, Norgaard Pedersen B, Lundemose JB, Rüdiger N, Gaustadnes M, Brandslund I. Sudden infant death syndrome, childhood thrombosis, and presence of genetic risk factors for thrombosis. *Thromb Res* 2000;98:233-9.
74. del Zoppo GJ, Hallenbeck JM. Advances in the vascular pathophysiology of ischaemic stroke. *Thromb Res* 2000;98:73-81.
75. Demir M, Vural Ö. Doku faktörü yolu inhibitörü: Normal hemostatik mekanizmada ve patolojik durumlardaki rolü. Ulutin ON (editör). *Tromboz, Hemostaz ve Anjiyoloji*. İstanbul: May Matbaacılık LŞ, 2001:20-32.
76. Öngören Ş, Uzel B, Aykut A, Köroğlu A, Ulutin ON, Ferhanoğlu B. Evaluation of risk factors in a cohort of patients suffering from thromboembolic events. *Turkish Journal of Haematology* 2000;17(Suppl 1):321(0-37).
77. Özşavcı D, Yardımcı T, Yanıkaya Demirel G, Hekim N, Ekşioğlu Demiralp, Uras F, Aydın H, Bayık M, Ulutin ON. Determination of platelet glycoprotein receptor numbers in hypercholesterolemia. *Turkish Journal of Haematology* 2000;17(Suppl 1):328-(P-3).
78. Ateş HÖ, Sayhan AN, Cengiz M, Ulutin T. Mutation detection of protein C gene in thrombosis patients. *Turk J Haematol* 2000;17(Suppl 1):348 (44).
79. Visseran FLJ, Bouwman JJM, Bouter KP, Diepersloot RJA, Ph G de Groot, Erkelens DW. Procoagulant activity of endothelial cell after infection with respiratory viruses. *Thromb Haemost* 2000;84:319-24.
80. Rapaport SI. Regulation of the tissue factor pathway. *Ann New York Acad Sci* 1991;614:51-62.
81. Nachman RL, Hajjar KA. Endothelial cell fibrinolytic assembly. *Ann New York Acad Sci* 1991;614:240-9.
82. Mikkelsen J, Perola M, Wartiovaara U, Peltonen L, Palotie A, Penttilä A, Karhunen PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle aged finnish men who died suddenly. *Thromb Haemost* 2000;84:78-82.
83. Cella G, Burlina A, Sbarai A, Motta G, Girolami A, Berrettini M, Straus W. Tissue factor pathway inhibitor levels in patient with homocystinuria. *Thromb Res* 2000;08:375-81.
84. Hooper WC, Lally C, Austin H, Renshaw M, Dille A, Wenger NK, Phillips DJ, Whitse C, Rawlins P, Evatt BL. The role of the t-PA I/D and PAI-1 4G/5G polymorphism in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism *Thromb Res* 2000;99:223-30.
85. Nakabayashi M, Yamamoto S, Suzuki K. Analysis of thrombomodulin gene polymorphism in women with severe early onset preeclampsia. *Seminars in Thromb Haemost* 1999;25:473-9.
86. Baker WF, Bick RL. Treatment of hereditary and acquired thrombophilic disorders. *Seminars in Thromb Haemost* 1999;25:387-406.
87. Dahlback B. Activated protein C resistance and thrombosis: Molecular mechanisms of hypercoagulable state due to FVR506Q mutation. *Seminars in Thromb Haemost* 1999;25:273-89.
88. Guba SC, Fonseca V, Fink LM. Hyperhomocysteinemia and thrombosis. *Seminars in Thromb Haemost* 1999;25:291-309.
89. Hong JJ, Kwaan HC. Hereditary defects in fibrinolysis associated with thrombosis. *Seminars in Thromb Haemost* 1999;25:321-31.
90. Bick RL, Baker WF. Antiphospholipid syndrome and thrombosis. *Seminars in Thromb Haemost* 1999; 25:333-50.
91. Villa P, Aznar J, Vaya A, Espana F, Ferrando F, Mira Y, Estellés A. Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis. *Thromb Haemost* 1999;82:1011-4.
92. Gardemann A, Lohre J, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. *Thromb Haemost* 1999;82:1121-6
93. Sakai H, Goto S, KIM JY, Aoki N, Abe S, Ichikawa N, Yoshida M, Nagaoka Y, Handa S. Plasma concentration of von willbrand factor in acute myocardial infarction. *Thromb Haemost* 2000;84:204-9.
94. Kılınc Y, Şaşmaz I, Antmen B, Tuncer R. Protein C deficiency associated with portal and renal vein. *Thromb Haemost* 2000;30(Suppl 1):144.
95. Küçükaya R, Aydın M, Önül A, Büyüköztürk K, Özbek U, Cenani A, Pekçelen Y. The frequency of platelet PLA2 polymorphism in Turkey and its association with coronary artery thrombosis in young patients. *Haemostasis* 2000;30:84.
96. Öngören S, Başlar Z, Aykut A, Köroğlu A, Ulutin O,

- Ferhanoglu B. Risk factor evaluation of a cohort of patients suffering thromboembolic events. *Haemostasis* 2000;30:132.
97. Sayhan N, Bayram Gürel Ç, Yılmaz T Ulutin, Ulutin ON. PCR-RFLP detection of PAI-2 gene variants and ACE gene polymorphism in myocardial infarction. *Haemostasis* 2000;30:140.
 98. Samama MM, Gerotziapas G, Conard J, Horellou MH, Elalamy I. Clinical aspects and laboratory problems in hereditary thrombophilia. LECTURES. In: Ulutin ON (ed). İstanbul: Meta Printing House, 1998:7-23.
 99. Agnes Henschen Edman. Identifying the beneficial and the detrimental properties of fibrinogen. LECTURES. In: Ulutin ON (ed). İstanbul: Meta Printing House, 1998:68-72.
 100. Badimon L, Royo T, Alfon J, Berrozpe M, Badimon JJ. Pathophysiology of atherosclerosis and thrombosis. LECTURES. In: Ulutin ON (ed). İstanbul: Meta Printing House, 1998:73-80.
 101. Fenton JW. Statins as cellular antithrombotics. LECTURES. In: Ulutin ON (ed). İstanbul: Meta Printing House, 1998:112-4.
 102. Bick RL, Arun B, Frenkel EP. Antiphospholipid thrombosis syndrome. LECTURES. In: Ulutin ON (ed). İstanbul: Meta Printing House, 1998:155-62.
 103. Mc Cormick TS, Lapetina EG. Macrophage resistance to apoptosis in atherogenesis. LECTURES. In: Ulutin ON (ed). İstanbul: Meta Printing House, 1998: 182-8.
 104. Walenga JM, Fareed J. Antithrombin and antifactor Xa drugs: Application in the management of cardiovascular disorders. *Turk J Haematol* 2000;17 (Suppl):35-47.
 105. Ağırbaşı M. The renin angiotensin system and vascular fibrinolytic balance. *Turk J Haematol* 2000;17 (Suppl):152-8.
 106. Ündar L. Protein Z. *Turk J Haematol* 2000;17 (Suppl):177-80.
 107. Meiselman HJ, Fisher TC, Armstrong JK. Red blood cell aggregation in thrombotic states. *Turk J Haematol* 2000;17(Suppl):197-202.
 108. Köksal F. *Chlamydia pneumoniae* and atherosclerosis. *Turk J Haematol* 2000;17(Suppl): 310.
 109. Altinkaya N, Uras F, Uras AR, Ulutin ON. Plasma tissue factor inhibitor in newborns and infants. *Turk J Haematol* 2000;17(Suppl):318.
 110. Özyürek HE, Aslan D, Gürgey A. Analysis of 129 children with thrombosis. *Turk J Haematol* 2000;17(Suppl):320.
 111. Öngören Ş, Uzel B, Aykut A, Köroğlu A, Ulutin O, Ferhanoglu B. Evaluation of risk factors in a cohort of patients suffering from thrombo-embolic events. *Turk J Haematol* 2000;17(Suppl):321(P-3).
 112. Ulutin T, Bayram Gürel Ç, Beyhan Özdaş Ş, Cengiz M, Yüksel A, Seven M. Tissue factor pathway inhibitor and coronary heart disease. *Turk J Haematol* 2000;17(Suppl):341(P-29).
 113. Sayhan N, Bayram Gürel Ç, Yılmaz Ş, Ulutin T. PCR-RFLP detection of PAI-2 gene variants and ACE gene polymorphism in myocardial infarction. *Turk J Haematol* 2000;17(Suppl):341(P-30).
 114. Ateş HÖ, Sayhan AN, Cengiz M, Ulutin T. Mutation detection of protein C gene in thrombosis patients. *Turk J Haematol* 2000;17(Suppl):348(P-44).
 115. Mouse SA. Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: Implications for management of vascular disorders. Seminar in Thromb Haemost 2000;26(Suppl 1):39-46.
 116. Uras F, Uras AR, Yardımcı T, Sardana MK. Determination of the N-terminal amino acid sequence of the purified prothrombin from a patient with liver cirrhosis. *Thromb Res* 2000;99:277-83.
 117. Xie L, Chesterman CN, Hogg PJ. Reduction of von Willebrand factor by endothelial cells. *Thromb Haemost* 2000;84:506-13.
 118. Mruk JS, Webster MWI, Heras M, Reid JM, Grill DE, Chesebro JH. Flavone-8-acetic acid (flavonoid) profoundly reduces platelet-dependent-thrombosis and vasoconstriction after deep arterial injury in vivo. *Circulation* 2000;101:324-8.
 119. Gimbrone MA Jr. Vascular endothelium: Nature's blood container. In: Gimbrone MA (ed). *Vascular Endothelium in Hemostasis and Thrombosis*. Edinburgh: Churchill Livingstone, 1986:1-3.
 120. Owen WG, Goeken AJ, Lollar P. Thrombin-endothelium interactions. In: Gimbrone MA (ed). *Vascular Endothelium in Hemostasis and Thrombosis*. Edinburgh: Churchill Livingstone, 1986:57-69.
 121. Monroe DM, Hoffman M, Allen GA, Roberts H. The factor VII-platelet interplay: Effectiveness of recombinant factor VIIa in the treatment of severe thrombocytopenia. *Seminars in Thromb Haemost* 2000;26:373-7.
 122. Herrmann FH, Wulff K, Auberger K, et al. Molecular biology and clinical manifestation of hereditary factor VII deficiency. *Seminars in Thromb Haemost* 2000;26:393-400.
 123. Berkarda B, Akogan S, Urgancıoğlu İ. A comparative study on the fibrinogen and platelets. *Haseki Tıp Bülteni* 1968;6:135-41.
 124. Balkuv Ulutin Ş, Aktuğlu G. The release of platelet antiplasmins. *New İstanbul Contr Clin Sci* 1974; 11:24-30.
 125. Balkuv Ulutin Ş, Latalo Z. Determination of the platelet antiplasmin with chromogenic substrate (2251) and comparison of the values obtained from atherosclerotics and normals. Intern Congr on Thrombosis of Mediterranean League for Thromboembolic Diseases, Monte Carlo, 1980,382.
 126. Balkuv Ulutin Ş, Girişgen G, Tunalı H, Uruluer S,

- Yiğitbaşı O, Toulemond F. Fibrinolytic treatment of experimental thrombosis with and without plasminogen prior to vasoactive agents. In: Ulutin ON, Berkarda B (eds). 1981 International İstanbul Symposia on Haematology. Kırklareli-Vize: Sermet Matbaası, 1981:109-21.
127. Ulutin ON. Atherosclerosis and haemostasis: Intra-ductory remarks. In: Ulutin ON, Berkarda B (eds). 1981 International İstanbul Symposia on Haematology. Kırklareli-Vize: Sermet Matbaası, 1981:3-12.
128. Ulutin ON, Yardımcı T, Çizmeçi G, Emekli N, Balkuv Ulutin Ş. Some observations on the alteration of hemostatic mechanism in atherosclerosis and its pathogenic relation to the disease. In: Ulutin ON, Vinazzer H (eds). Thrombosis and Hemorrhagic Diseases. İstanbul: Gözlem Printing and Publishing Co, 1985:1-4.
129. Kansu E, Şahin G, Şahin F, Sivri B, Karacadağ Ş, Duru S, Telatar H, Batman F, Kansu T, Dündar S, Akkaya S, Zileli T. Plasma prostacyclin levels in Behçet's disease. In: Ulutin ON, Vinazzer H (eds). Thrombosis and Hemorrhagic Diseases. İstanbul: Gözlem Printing and Publishing Co, 1985:272-4.
130. Yardımcı TU. Membrane transport systems in human platelets. *Haematologica* 1980;65:498-508.
131. Gross PL, Aired WC. The endothelium and thrombosis. *Semin in Thromb Hemast* 2000;26:463-78.
132. Schiekofe S, Balletschofer B, Andrassi M, Bierhauser A, Nawroth PP. Endothelial dysfunction in diabetes mellitus. *Semin in Thromb Hemast* 2000;26:503-11.
133. Gimbrone MA Jr. Endothelial dysfunction and pathogenesis of atherosclerosis. In: Gotto A (ed). *Atherosclerosis V*. New York: Springer Verlag, 1980: 415-25.
134. Nawroth PP, Stern DM. Endothelial cells as active participants in procoagulant reactions. In: Gimbrone MA (ed). *Vascular Endothelium in Hemostasis and Thrombosis*. Edinburgh: Churchill Livingstone, 1986:14-39.
135. Avcu F, Akar E, Demirkılınç U, Yılmaz E, Akar N, Yalçın A. The role of prothrombotic mutations in patients with buerger disease. *Thromb Res* 2000;100: 143-7.
136. Ulutin ON, Şestakof D. A study on hypercoagulability using heparin loading test. *Henry Ford Hosp Med Bull* 1960;8:63-7.
137. Ulutin ON. Heparin loading test. In: Wright IS, Koller F, Beck E (eds). *Heparin and Thromboplastin with a Survey on von Willebrand's Disease*. Stuttgart: Friedrich-Karl Schattauer-Verlag, 1962:72-3.
138. Klein B, Faridi A, Amo-Takyi. BK, Heilmann L, von Tempelhoff BK, Rath W. Neonatal platelet activation in preeclampsia. *Clin Appl Thrombosis/Hemostasis* 2001;7:29-32.
139. Preissner KT. Hemostatic protease receptors and endothelial cell function: Insights from gene targeting in mice. *Semin in Thromb Hemast* 2000;26:451-62.
140. Gross PL, Aird WC. The endothelium and thrombosis. *Semin in Thromb Hemast* 2000;26:463-47.
141. Yee KO, Ikari Y, Schwartz SM. An update of the Grützbald hypothesis: The role of thrombosis and coagulation in atherosclerotic progression. *Thromb Haemost* 2001;85:207-17.
142. Osterud B. A global view on the role of monocytes and platelets in atherosclerosis. *Thromb Res* 1997;85:1-22.
143. Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. *Thromb Haemost* 2001;85:584-95.
144. Wehrmacher WH. Endothelium: From whence to whither. *Seminars in Thromb Hemast* 1988; 14(Suppl):1-11.
145. MacMillan GJ. Nature and definitions of atherosclerosis. *Ann NA Acad Sci* 1985;452:1-4.
146. Sinzinger H, Widhalm K. Atherosclerose seit der zeit der pharaonen. *Österreich Arztezeitung* 1981; 20:1.
147. von Rokitsky K. *Handbuch Deer Pathologischen Anatomie*. Berlin: Braunnüller & Seidel, 1841.
148. Virchow R. Phlogose und thrombose in gefasssystem. *Gesammelte Abhandlungen zur Wissenschaftlichen Medizin*. Frankfurt/Main: Meidinger, 1856:458-63.
149. Ross R. The pathogenesis of atherosclerosis: An update. *N Engl J Med* 1986;314:488-500.
150. Brevetti G, Martone VD, Cristofone T, Corrado S, Silvestro A, Di Donato AM, Bucur R, Scopacasa F. High levels of adhesion molecules are associated with impaired endothelium dependent vasodilation in patients with peripheral arterial disease. *Thromb Haemost* 2001;85:63-6.
151. Rosendaal. Hemostatic risk factors. *Thromb Haemostas* 2001;85:584-95.
152. Irelund H, Kunz G, Kyriakoulous K, Stubbs PJ, Lane DA. Thrombomodulin gene mutations associated with MI. *Circulation* 1997;96:15-8.
153. Booth NA. TAFI meets the sticky ends. *Thromb Haemost* 2001;85:1-2.
154. Mosnier LO, Meijers JCM, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. *Thromb Haemost* 2001;85:5-11.
155. Ünlüer A, Avanoğlu Y, Erdağ A, Yardımcı T. Glycogen levels in the platelets of normal and atherosclerotic cases. In: Ulutin ON, Vinazzer H (eds). *Thrombosis and Hemorrhagic Diseases*. İstanbul: Gözlem Printing House, 1986:425-8.
156. Ulutin ON, Şestakof D. Hiperkoagülabilité üzerinde bir çalışma. *Türk Tıp Cem Mec* 1957;24:47-51.
157. Balkuv Ş, Ulutin ON. Fibrinolizis. 1968 *Türk Tabib-*

- ler Birliđi Yıllığı 1968:39-50.
158. Aktulga AZ, Ulutin ON. Normal ve patolojik durumlarda trombosit fosfolipid dağılımı. *Hematoloji V* 1975:189-93.
159. Aktulga AZ, Ulutin ON. Some observations on platelet fibrinogen and its secretion. In: Ulutin ON (ed). *Platelets: Recent Advances in Basic Research and Clinical Aspects*. Amsterdam: Excerpta Medica, 1975:185-91.
160. Braquet P, Bourgain R, Mencia-Huerta JM. Effect of platelet activating factor on platelets on vascular endothelium. *Semin Thromb Hemast* 1992;15:184-99.
161. Şirikci Ö. Lipoprotein (a) ve ateroskleroz. 1. Biyokimya Günleri: Ateroskleroz ve Lipid Biyokimyası Sempozyumu 16-17, Haziran, Mersin, 2000.
162. Ulutin ON. Atherosclerosis, haemostasis and thrombosis. Toyama International Symposium on Thrombosis, Hemostasis/Laboratory Medicine. Toyama, Japan 1999;12:11-4.
163. Ulutin ON. Atherosclerosis, Haemostasis and Thrombosis. State of Art Lectures 16th Intern Congr on Thrombosis, Porto, Portugal, May 5-8, 2000:69-73.
164. Prydz H. Aspects of the cell biology of tissue factor. State of Art Lectures 16th Intern Congr on Thrombosis, Porto, Portugal, May. 5-8, 2000:86-7.
165. Aiach M, Arnoud E, Athene-Gelas M, Nicaud V, Fiesinger JN, Emmerich J. Genetic risk factors associated with venous thrombosis. 16th Intern Congr on Thrombosis, Porto, Portugal, May 5-8, 2000: 29-32.
166. Schved JF, Giansily M. Tissue factor and tissue factor pathway inhibitor. 16th Intern. Congr on Thrombosis, Porto, Portugal, May 5-8, 2000:78-81.
167. Altinkaya N, Uras F, Çetin E, Ersoy Ş, Uras AR, Ulutin ON. Plasma tissue factor pathway inhibitor in New Borns and infant. *Haemostasis* 1998;28 (Suppl +2):357.
168. Kanigür Sultuybey G, Tezcan V, Güven M, Taşan T, Cenani A, Hatemi H, Ulutin ON. The relationship between aging and the changes insulin receptors and glucose transport of human erythrocytes. Honorary Volume for Prof. P. Balas of Hellenic Vascular Surgical Society, 1993:475-9.
169. Çizmeçi G, Ulutin ON. Platelet prostoglandins in atherosclerosis. *Thromb Haemost* 1983;50:428.
170. Sütsch G, Wenzel R, Kiowski W, Lüscher TE. Endothelin and its role in vascular physiology/biology. In: Born GV, Schwartz CJ (eds). *Vascular Endothelium*. Stuttgart/New York: Schattauer, 1997:221-42.
171. Sönmez H, Suer S, Kökođlu E, Dirican A, Ulutin T, Üçışık N, Ulutin ON. The importance of Lp(a)-fibrinogen interacts in atherogenesis. *Haematologia* 1997;28:149-53.
172. Rapaport SI, Mohan Rao LV. The tissue factor pathway: How it has become "prima Ballerina". *Thromb Haemost* 1995;74:7-17.
173. Tokgözođlu Sİ, Alikasıfođlu M, Tunçbilek E, Atalar E, Uysal Ö, Şimşek H, Övünç K, Aksoyek Ş, Kabbakçı G, Kes S. ACE polymorphism is not associated with the presence and extent of CAD, MI or aneurysm formation in the Turkish population. *Haemostasis* 1998;28(Suppl 2):120.
174. Akar N, Mısırlıođlu M, Akar E, Sözüöz A, Avcu F, Yalçın A, Cin Ş. PT 20210 G-A and FV mutations in Turkish population. *Haemostasis* 1998;28(Suppl 2):155.
175. Akar, N, Akar E, Mısırlıođlu M, Avcu F, Yalçın A, Cin Ş. Search for genetic factors favoring thrombosis in Turkish population. *Haemostasis* 1998;28(Suppl 2):162.
176. Ünal A, Öktem İS, Çetin M, Çelik İ, Akdemir H. Activated protein C resistance with deep venous thrombosis, recurrent pulmonary embolism, and cerebral hemorrhage; succesful treatment with fresh frozen plasma. *Haemostasis* 1998;28(Suppl 2):221.
177. Yiđit Ş, Kemahlı S, Akar N, Gürman C, Uzunali Ö, Cin Ş. Fibrinolytic activity in neonate. *Haemostasis* 1998;28(Suppl 2):310.
178. Ezer Ü, Yüksel S, Kapuađası A, Gürsoy S. Hemorrhagic diseases of the newborn. *Haemostasis* 1998; 28(Suppl 2):311.
179. Tokgözođlu Sİ, Alikasıfođlu M, Atalar E, Aytemir K, Özer N, Ünsal İ, Usal Ö, Şimşek H, Övünç K, Kes S, Tunçbilek E. MTHFR gene polymorphism predicts the presence and extent of coronary atherosclerosis. *Haemostasis* 1998;28(Suppl 2):337.
180. Sönmez H, Suer S, Ulutin T, Kökođlu E, Domaniç N. The relationship of various factors in the pathogenesis of atherosclerosis. *Haemostasis* 1998;28 (Suppl 2):342.
181. Ulutin T, Bayram Ç, Bolat F, Domaniç N. Tissue factor pathway inhibitor in patients with coronary heart disease. *Haemostasis* 1998;28(Suppl 2):395.
182. Tanrıverdi K, Aıkımbaev K, Gürkan E, Başlamışlı İF, Koçak R. Factor V Leiden, protein C and antithrombin in patients with thrombosis in southern Turkey. *Haemostasis* 1998;28(Suppl 2):399.
183. Kurt C, Tanrıverdi K, Koçak R. The frequency of factor V Leiden in southern of Turkey. *Haemostasis* 1998;28(Suppl 2):407.
184. Gürgey A, Parlak H, Balta G, Altay Ç. Factor V Leiden, prothrombin 20210 A and MTHFR C677T mutations in Turkish patients with thrombosis and normal population. *Haemostasis* 1998;28(Suppl 2):411.
185. Kavaklı K, Ireland H, Akisu M, Kültürsay N, Çetingül N, Polat A, Aydınok Y, Nişli G. Purpura fulminans due to homozygous protein C deficiency in a neonate. *Haemostasis* 1998;28(Suppl 2):430.
186. Domaniç N, Ural D, Vural VA, Bayram Gürel Ç, Ulu-

- tin T. Factor VII levels in coronary artery disease. *Haemostasis* 1988;28(Suppl 2):513.
187. Gözdaşoğlu S, Ertem M, Çavdar AO, Emre T, Gürman C. Congenital factor VII deficiency. A case report for a rare bleeding disorder. *Haemostasis* 1988;28(Suppl 2):533.
188. Avcu F, Akar E, Mısırlıoğlu M, Ural AU, Yalçın A, Akar N. The role of factor V Leiden, prothrombin gene G-A, and metylenetetrahydrofolate reductase 677 C-T mutations in patient with venous thrombosis. *Haemostasis* 1998;28(Suppl 2):570.
189. Demir M, Vural Ö, Sunar H, Altun A, Yorulmaz F, Özbay G. Natural inhibitors and resistance to activated protein C in venous and arterial thrombosis. *Haemostasis* 1998;28(Suppl 2):572.
190. Ören H, Ünsal E, İrken G, Grohmann A, Nauck D, Sutor AH. Evaluation of the hypercoagulable state in pediatric patients with collagen vascular diseases and familial Mediterreanean fever. *Haemostasis* 1998;28 (Suppl 2):574.
191. Akar N, Akar E, Avcu F, Yalçın A. Endothelial nitric oxide intron 4, 27 BP repeat polymorphism in Turkish population. *Haemostasis* 1998;28(Suppl 2):591.
192. Hoffman M, Monroe III DM. A cell-based model of hemostasis. *Thromb Haemost* 2001;85:958-65.
193. Ulutin ON. The pathogenesis and laboratory findings of atherosclerosis from hemostasis standpoint. In: Michalopoulos ChD, Mandalaki T (eds). Symposium on Hemostasis-Thrombosis; Theory and Clinical Practice. Sept. 8-9, 2000, Athens Archives of Hellenic Medicine 2000;17(Suppl A):44-50.
194. Vascular Endothelium. In: Born GVR, Schwartz CJ (eds). Stuttgart, Schattauer, 1997:1-391.
195. A History of Blood Coagulation By Charles Owen A. In: William L Nichols, Walter Bowie EJ, Rochester (eds). Mayo Foundation for Medical Education and Research, Minnesota, 2001.
196. Sönmez H, Süer S, Ulutin T, Kökoğlu E, Üçışık N. The relationship of various factors in the pathogenesis of atherosclerosis. *Clin Appl Thrombosis/Hemostasis* 1998;4:105-10.
197. Sakai H, Goto S, Kim JY, Aoki N, Abe S, Ichikawa N, Yoshida M, Nagaoka Y, Handa S. Plasma concentration of von Willebrand factor in acute myocardial infarction. *Thromb Haemost* 2000;84:204-9.
198. Moatti D, Haidar B, Fumeron F, Gauci L, Boudvillain O, Seknadji P, Ollivier V, Aumont MC, de Prost, D. A new T-287 C polymorphism in the 5' regulatory region of the tissue factor pathway inhibitor gene; association study of the T-287 C and C-399T polymorphism with Coronary Artery Disease and plasma TFPI levels. *Thromb Haemost* 2000;84:244-9.
199. Ulutin ON. Ateroskleroz ve hiperkoagülabilite. *Türkiye Tıp Akademisi Mecmuası* 1969;4:76-88.
200. Balkuv Ş. Fibrinolizis ve aterosklerozis. *Türkiye Tıp Akademisi Mecmuası* 1969;4:114-24.
201. Kanıgür-Sultuybek G, Hatemi H, Güven M, Ulutin T, Tezcan V, Ulutin OU. The effect of metformin and gliclazide on platelet and red blood cell glucose tolerance mechanisms in impaired glucose tolerance and type II diabetic patients with vasculopathy. *Thrombotic and Hemorrhagic Disorders* 1993;7:17-22.
202. Taute BM, Seifert R, Taute R, Glaser C, Podhaisky H. Angiotensin-converting enzyme gene insertion/deletion polymorphism and carotide artery wall thickness in patients with peripheral arterial occlusive disease. *International Angiology* 2000;19:337-44.
203. Giesen PLA, Nemerson Y. Tissue factor on the loose. *Semin in Thromb Hemast* 2000;26:379-83.
204. Sultuybek G, Hatemi H, Güven M, Ulutin T, Bayram Ç, Tezcan V. The effect of Metformin and gliclazide on platelet and red blood cell glucose transport mechanisms and Haemostatic system in impaired glucose tolerance and type 2 diabetic patients with vasculopathy. *Haemostasis* 1998;28(Suppl 2):343.
205. Demir M, Vural Ö. Doku faktörü yolu inhibitörü: Normal hemostatik mekanizmada ve patolojik durumlardaki rolü. Ulutin ON (editör). Tromboz, Hemostaz ve Anjioloji. İstanbul: May Matbaacılık LŞ, 2001:20-32.
206. Morrissey JH. Tissue factor: An enzyme cofactor and a true receptor. *Thromb Haemost* 2001;86:66-74.
207. Bertina RM. Genetic approach to thrombophilia. *Thromb Haemost* 2001;86:92-103.
208. Konigsberg W, Kirchofer D, Riederer MA, Nemerson Y. TF: VIIa complex: Clinical significance, structure-function relationships and its role in Signaling and metastasis. *Thromb Haemost* 2001;86:757-71
209. Poredos P. Endothelial dysfunction in the pathogenesis of atherosclerosis. *Clinical and Applied Thrombosis/Hemostasis* 2001;7:276-80.
210. Tromboz, Hemostaz ve Anjioloji. Ulutin ON (editör). İstanbul: May Matbaacılık Ltd Ş, 2001:7-299.
211. Maxwell M Wintrobe. Hematology, the blossoming of a science: A story of inspiration and effort. Philadelphia: Lea & Febiger, 1985.
212. Bick RL. Antiphospholipid thrombosis syndrome. *Clinical and Applied Thrombosis/Hemostasis* 2001;7:241-58.
213. Kemkes Matthes B, Matthes KJ. Protein Z. *Seminars in Thromb Haemost* 2001;27:551-6.
214. Özdamar E. Aterosklerozlularda heparin tayini. *Thrombosis and Anticoagulants, I. Istanbul Symposium, Oct.15-16,1964* In: Garan R, Ulutin ON (eds). New İstanbul Contribution to Clinical Science 1965; (Suppl 1):126-8.
215. Özdamar E. Endogenous and postheparin plasma levels in cases of cerebral atherosclerosis. *Med*

- Bull İstanbul 1968;1:50.
216. Karaca M, Koşay E. Hiperkoagülabilite hallerinde heparin yükleme testinin tetkiki ve ehemmiyeti. Ege Tıp Cem Mec 1964;2:12.
217. Ulutin ON, Akman N, Aktulga AZ, Emekli NB, Uğur MŞ, Ulutin ŞB. The alteration of haemostatic mechanism in atherosclerosis. New İstanbul Contribution to Clinical Science 1977;12:92-101.
218. Yüceyar N, Kumral E, Tombuloğlu M, Özsan H. Prethrombotic coagulation abnormalities in young adults with ischaemic stroke. Turk J Haematol 1998;15:83-90.
219. Zarrinanbour H, Keser G, Dönmez A, Çağırğan S, Oksel F, Aksu K, Tombuloğlu M. Activated protein C resistance in Behçet's disease. Turk J Haematol 2000;17:73-6.
220. Münzel T, Just H, Harrison DG. The physiology and pathophysiology of nitric oxide/superoxide system. In: Born GVR, Schwartz CY (eds). Vascular Endothelium. Stuttgart/New York: Schattauer, 1997:205-20.
221. Badimon L, Royo T, Alfon J, Berrozpe M, Badimon JJ. Pathophysiology of atherosclerosis and thrombosis. In: Ulutin ON (ed). LECTURES. 1998:73-80.
222. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Suenram CA, Graves DT, Rozek MM, Edwards EH, Delgado R. Monocyte-macrophage participation in atherosclerosis: Inflammatory components of pathogenesis. Seminars in Thrombosis and Atherosclerosis 1986;12:79-90.
223. Zan, S-p, Xu, D-y. Oxidized lipoprotein (a) enhanced the expression of p-selectin in cultured human umbilical vein endothelial cell. Thromb Res 2000;100: 501-10.
224. Ulutin ON, Akman N. Heparin loading test, testin thromboelastography'e tatbiki ve hiperkoagülabilite. In: Garan R, Ulutin ON (eds). Thrombosis and Anticoagulants. New İstanbul Contr Clin Sci 1965:8 (Suppl 1):119-25.
225. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-5.
226. Akar N. Pediatrik trombozda moleküler değişimler. Ulutin ON (editör). Tromboz, Hemostaz ve Anjiyoloji. İstanbul: May Matbaacılık Lt Ş 2001:106-12.
227. Ulutin ON, Gürsoy A. Platelet AT-III in normal persons and in atherosclerotic. Ann Univ Saray Med 1983;(Suppl 3):149-50.
228. Gürsoy A, Ulutin ON. Platelet antithrombin III. Ann Univ Saray Med 1983;(Suppl 3):75-8.
229. Koltai M, Hosford D, Bourgain RH, Braquet P. The role of PAF in blood cell-vessel wall interactions and atherosclerosis. Thromb Haemorrh Disorders 1990; 2:47-60.
230. Uras F. Neonatal tromboembolik olaylarda laboratuvar. Ulutin ON (editör). Tromboz, Hemostaz ve Anjiyoloji. İstanbul: May Matbaacılık Lt Ş. 2001:207-16.
231. Akar N. Pediatrik trombozda moleküler değişimler. Ulutin ON (editör). Tromboz, Hemostaz ve Anjiyoloji. İstanbul: May Matbaacılık Lt Ş. 2001:106-14.
232. Balkuv Ulutin Ş. Fibrinolitik sistem: Temel mekanizmalar. In: Ulutin ON (ed). Tromboz, Hemostaz ve Anjiyoloji. İstanbul: May Matbaacılık Lt Ş. 2001:127-35.
233. Kavaklı K, Aydınok Y, Yılmaz D, Balım Z, Çetingül N, Kansoy S, Kantar M, Aksoylar S, Tütüncüoğlu S, Aydoğdu S, Özyürek Kültürsay N, Özkınay C, Özkınay F. Ege Üniv Tıp Fak Pediatrik Tromboz olgularının dökümü. Ulutin ON (editör). Tromboz, Hemostaz ve Anjiyoloji. İstanbul: May Matbaacılık Lt Ş. 2001:255 (P-2).
234. Ulutin ON. Structure and function of platelets and its defects. Proceedings 4th Meeting Asian-Pacific Division, ISH. In: Lee M, Hang GY, S. in Kim (eds). Seul: Korea Green Cross Corp, 1980:33-43.
235. Aktulga AZ, Ulutin ON. Platelet antithrombin III in atherosclerosis. Thromb Haemost 1977;38:275.
236. Yardımcı TU. The effect of osmotic shock on platelet membrane transport. Haematologica 1980; 65:516-32.
237. Balkuv Ş, Ulutin ON. Platelet osmotic resistance test depending on potassium release. IVth Congr Asian-Pacific Soc Hemat, Nov 14-17, 1967 New Delhi, India.
238. Ulutin ON, Karaca M. A study on the pathogenesis of thrombopathia using "platelet osmotic resistance test". Brit J Haematol 1959;5:302.
239. Ulutin ON, Riddle JM, Rebeck JW. Platelet osmotic resistance test using the electron microscope. New İstanbul Contr Clin Sci 1963; 6:142.
240. Broze GJ, Miletich JP. Human protein Z. J Clin Invest 1984;73:933-8.
241. Usulan C, Erdem Y, Altun B. Protein C levels in haemodialysis patients. Int Urol Nephrol 1999;31: 541-5.
242. Ündar L, Karadoğan I, Öztürk F. Plasma levels of protein Z inversely correlate with plasma interleukin 6 levels in patients with acute leukemia and non-Hodgkin lymphoma. Thromb Res 1999;94:131-4.
243. Emekli N, Ulutin ON. 14 C-galactose transport in human platelets. VIth Intern Congr on Thrombosis of Mediterranean League against Thromboembolic Diseases, Monaco.
244. Çizmecci G, Yardımcı TU, Aytış Ş. Platelet membrane transport of arachidonic acid in normal subjects and atherosclerotics. In: Palos L, Vinazzer H (eds). Antithrombin III, Platelets and Thrombosis Fibrinolysis. Würzburg: SCHmitt and Mayer, 1982:83-8.
245. Çizmecci G, Aytış Ş, Ulutin ON. Transport of Arachidonic acid (AA) across platelet membrane and PG metabolism in atherosclerosis. In: Ulutin ON, Berkarda B (eds). 1981 Internat İstanbul Symposium

- on Haematology. Kırklareli, Vize: Sermet Matbaası, 1982:55-62.
246. Emekli MB, Ulutin ON. The effect of cyclooxygenase inhibitor on the glycoprotein synthesis. In: Ulutin ON, Berkarda B (eds). 1981 Intern İstanbul Symp on Haematology. Kırklareli, Vize: Sermet Matbaası, 1982:185-90.
247. Ulutin ON, Çizmeçi G, Yardımcı T, Emekli N, Gürsoy A, Balkuv Ulutin Ş. Function and Biochemistry of platelets in atherosclerosis-thromboembolism. Grupo Cooperative Latino-Americano de Hemostasis y Trombosis Symposia, Buenos Aires, 1984:47-52.
248. Sultuybek G, Hatemi H, Güven M, Ulutin T, Bayram Ç, Tezcan V. The effect of Metformin and gliclazide on platelet and red blood cell glucose transport mechanisms and Haemostatic system in impaired glucose tolerance and type 2 diabetic patients with vasculopathy. *Haemostasis* 1998;28(Suppl 2):343.
249. Yardımcı T, Yaman A, Ulutin ON. The characterisation of platelet GGT and its alteration in the cases of atherosclerosis. *Clinical and Applied Thrombosis/Hemostasis* 1995;1:103-13.
250. Avanoğlu Y. The alteration of glucose utilization and lactate formation of platelets in the cases of atherosclerosis. In: Ulutin ON, Vinazzer H (eds). *Thrombosis and Hemorrhagic Diseases*. İstanbul: Gözlem Printing and Publishing Co, 1986:417-24.
251. Kansu E. Behçet hastalığında endotel disfonksiyonu. Ulutin ON (editör). *Tromboz, Hemostaz ve Anjiyoloji*. İstanbul: May Matbaacılık Lt Ş, 2001:59-65.
252. Müftüoğlu AÜ, Yurdakul S, Yazıcı H. Vascular involvement in Behçet's disease: A review of 129 cases. In: Lehner T, Barnes CG (eds). *Recent Advances in Behçet's Disease*. London: Royal Society of Medicine, 1986:255-60.
253. Yazıcı H, Hekim N, Özbakır F. von Willebrand factor in Behçet's syndrome. *J Rheumatol* 1987;14:305-6.
254. Kansu E, Sivri B, Şahin G. Endothelial cell dysfunction in Behçet's disease. In: Duffy JDQ, Kökmen E (eds). *Behçet's Disease-Basic and Clinical Aspects*. New York: Marcel Dekker Inc, 1991:523-30.
255. Özorun K, Düğün N, Gürler A, Tutkak H, Tokgöz G. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator, inhibitor and anti-thrombin III levels in Behçet's disease. *Scand J Rheumatol* 1995;24:376-82.
256. Demirel S, Sengül N, Yerdel MA, Tüzüner A. Haemostasis in patients with Behçet's disease. *Europ J Vasc Endovasc Surg* 2000;19:570-4.
257. Ohdama S, Takano S, Miyake S. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular disease. *Am J Pathol* 1994;101:109-13.
258. Ulutin ON. Normal ve patolojik durumlarda endotel hücre fonksiyonu. Yalçın Tüzün (editör). *Dermatolojide Gelişmeler*. İstanbul: Teknografik Matbaacılık, 1991:89-98.
259. Behçet H. Über rezidivierende aphtose, dorch ein virus verursachte Geschwüren am Mund, am Auge und an den Genitalen. *Dermatol Wochenschr* 1937;105:1152-7.
260. Fressinet JM, Toti F, Hugel B, Gidon-Jeangirard C, Kunzelman C, Martinez MC, Meyer D. Apoptosis in vascular disease. *Thrombosis and Haemostasis* 1999;82:727-35.
261. Roubey RAS. Immunology of the antiphospholipid syndrome: Antibodies, antigens, and autoimmune respons. *Thrombosis and Haemostasis* 1999; 82:656-61.
262. Gimbrone MA. Endothelial dysfunction and the pathogenesis of atherosclerosis. In: Fidge NH, Nestel PJ (eds). *Atherosclerosis VII. Proc. of 7th Intern Symp on Atherosclerosis*. Amsterdam: Excerpta Medica, 1986:367-9.
263. Kavaklı K. Hemofili'de inhibitör sorunu ve inhibitör tedavisinde en son gelişmeler. Ulutin ON (editör). *Tromboz, Hemostaz ve Anjiyoloji*. İstanbul: May Matbaacılık Lt Ş, 2001:7-27.
264. Ulutin ON, Tunalı H, Demirkol F, Eerbengi T. The effects of LMW and HMW heparin on the electrically induced thrombosis in dogs (Preliminary Study). In: Ulutin ON, Vinazzer H (eds). *Thrombosis and Hemorrhagic Diseases*. İstanbul: Gözlem Printing & Publishing Co, 1985:412-5.
265. Çakır N. Apoptozis ve otoimmünite. *Trombus, Hemostaz ve Anjiyoloji*. May Matbaacılık Lt Ş, 2001: 151-7.
266. Ulutin ON, Becit N, Aktuğlu G. Synthesis of factor VIII-like activity in leucocytes cultured from normal healthy donors and Hodgkin's. *New İstanbul Contribution Clinical Science* 1972;10:139-41.
267. Yardımcı TU, Aktulga AZ, Ulutin ON. Palmitic acid transport in platelets of normal and cirrhosis platelets. *Acta Haemat* 1980;63:2-6.
268. Özbilen A, Yardımcı TU, Ulutin ON. Leucin transport in platelets. *Haematologica* 1980;65:544-651.
269. Yardımcı TU, Özbilen A, Ulutin ON. Some observations on platelet aminoacid transport systems. *Haemostasis* 1982;12:498.
270. Ulutin ON. The platelet secretion mechanisms in normal and in pathological conditions. *J Med Enzymol (Tokyo)* 1977;2:86-103.
271. Gürsoy A, Özbilen A, Ulutin ON. Platelet prostaglandin F2a (PGF2a) in atherosclerosis. *Thrombos Haemosts (Stuttgart)* 1979;42:485.
272. Ulutin ON. The alterations of platelet in cases of atherosclerosis showing hypercoagulability. In: Vinazzer H (ed). *Forschungsergebniss der Transfusionsmedizin und Immunohaematologie*. Berlin: Medicus Verlag GmbH, 1979:179-81.
273. Ulutin ON. Functional and biochemical alteration of platelets in atherosclerosis and thromboembolism. In: Davidson JF, C  pelak V, Samama MM, Desnoyers PC (eds). *Progress in Chemical Fibrinolysis*

- and Thrombolysis. Edinburgh: Churchill Livingstone, 1979;4:260-5.
274. Ulutin ON. The alteration of platelets in atherosclerosis. *Quademi Delli Coagulazione* 1980;227-30.
275. Ulutin ON, Riddle JM, Rebeck JW. Platelet osmotic resistance test using electronmicroscope. *New İstanbul Contr Clin Sci* 1963;6:142-9.
276. Binak K, Müftüoğlu AÜ, Balkuv Ş, Harmancı N, Ulutin ON. The difference in the coagulation activity between arterial and sinus coronary blood in normals and arteriosclerosis. *New İstanbul Contr Clin Sci* 1967;9:171-8.
277. Ulutin ON, Yaramancı T, Ulutin ŞB. The release mechanism of platelets in normals and in pathological condition from coagulation and und ultrastructural standpoint. *Acta Univ Carol Med Monographia LIII-IV*, 1972:305-15.
278. Moncada S, Palma RMJ, Higgs EP. Prostacyclin and endothelium derived relaxing factor biological interaction and significance. In: Verstaete M, Vermeylen J, Lijnen HR, Arnoud J (eds). *Luven Univ Press* 1987:597-18.
279. Aktulga A, Ulutin ON. Some observations on platelet fibrinogen and its secretion. In: Ulutin ON, Verrier Jones J (eds). *Platelets: Recent Advances in Basic Research and Clinical Aspects*. Amsterdam: Excerpta Medica, 1975:150-61.
280. Krzywaneck HJ, Breddin H. Further evidencethat enhanced spontaneous platelet aggregation is a risk factor in the occurrence of thromboembolic complications in vascular disease. In: Ulutin ON, Verrier Jones J (eds). *Platelets: Recent Advances in Basic Research and Clinical Aspects*. Amsterdam: Excerpta Medica, 1975:354-60.
281. Ulutin ŞB, Aktulga A, Aktuğlu G, Emekli NB, Erbençi T, Güler M, Uğur MŞ, Ulutin ON. Observations on the effects of antiaggregating drugs on platelet function. In: Ulutin ON, Verrier Jones J (eds). *Platelets: Recent Advances in Basic Research and Clinical Aspects*. Amsterdam: Excerpta Medica, 1975:282-91.
282. Yurdakök M. Anticoagulan proteins and fibrinolytic system in newborn Infants. *Turkish J Haematology* 2000;17(Suppl):217-27.
283. Altinkaya N. Yenidoğanda hemostaz. Ulutin ON (editör). *Tromboz, Hemostaz ve Anjiyoloji*. İstanbul: May Matbaacılık Lt Ş, 2001:197-201.
284. Kemahlı S. Yeni doğanda tromboz. Ulutin ON (editör). *Tromboz, Hemostaz ve Anjiyoloji*. İstanbul: May Matbaacılık Lt Ş, 2001:202-6.
285. Vinazzer H. The alteration of antithrombin III, protein C and other natural inhibitors in atherosclerosis and thromboembolis. In: Ulutin ON, Vinazzer H (eds). *Thrombosis and Hemorrhagic Diseases*. İstanbul: Gözlem Printing & Publishing Co, 1986:6-16.
286. Sandset PM. The role of tissue factor pathway inhibitor as a physiological anticoagulant. In: Ulutin ON (ed). *LECTURES-1995*. İstanbul: Meta Basım Yayıncılık Senayi ve Ticaret Lt Ş, 1995:183-9.
287. Jaques LB. Spontaneous hemorrhage and stress. *New İstanbul Contr Clin Sci* 1973; 10:171-87.
288. Jacques LB. Heparin. *New İstanbul Contr Clin Sci* 1973;10:208-21.
289. Yardımcı TU, Balkuv Ulutin Ş. Histidine active transport system in rabbit erythrocytes. *New İstanbul Contr Clin Sci* 1976;11:131-5.
290. Ulutin ON, Harmancı N, Binak K, Akman N. Aynı zamanda alınan arteria brachialis ve koroner sinüs kanları arasındaki koagülasyon aktivitesi farkı. *Garan R, Ulutin ON (editörler)*. *Thrombosis and Anticoagulants*. İstanbul: Sermet Matbaası, 1965:113-8.
291. Ulutin ON. Yedinci faktörün kan koagülasyonundaki rolü. *Türk Tıp Cem Mec* 1957;23:617-20.
292. Berker F, Ulutin ON, Karaca M. Bir konjenital 7'inci faktör eksikliği "Konjenital hipoprokonvertinemi vaka"sı ve bu bahse umumi bir bakış. *Türk Tıp Cem Mec* 1958;24:318-22.
293. Akman N, Emekli N, Ulutin ON. A Case of Congenital Hypoprothrombinemia (Factor II deficiency). *IVth Meeting of European-African Div, ISH, 5-7 Sep 1977, İstanbul*.
294. Ayaz M, Avanoğlu Y, Aktuğlu G, Ülkü B, Akman N, Müftüoğlu A, Ulutin ON. Haemophilia and haemophilia-like diseases. In: Ulutin ON, Vinazzer H (eds). *Thrombosis and Hemorrhagic Diseases*. İstanbul: Gözlem Printing & Publishing Co, 1986:438-42.
295. Devocioğlu Ö. rVIIa (Novoseven)'in trombosit hastalıklarında kullanımı. Ulutin ON (editör). *Tromboz, Hemostaz ve Anjiyoloji*. İstanbul: May Matbaacılık Lt Ş, 2001:142-5.
296. Kavaklı K. Hemofilide inhibitör sorunu ve inhibitör tedavisinde son gelişmeler. Ulutin ON (editör). *Tromboz, Hemostaz ve Anjiyoloji*. İstanbul: May Matbaacılık Lt Ş, 2001:7-19.
297. Ulutin ON, Balkuv Ulutin Ş. The dog thrombosis model using electrically stimulation and some results using this model. In: Breddin K, Zimmermann R, Schattauer Verlag FK (eds). *Standardization of animal models of thrombosis, 17. Angiological Symp Kitzbühel. Stuttgart-New York 1983:83-90*.
298. Taubman MB, Giesen PLA, Schecter D, Nemerson Y. Regulation of the procoagulant response to arterial injury. *Thrombosis and Haemostasis* 1999;82: 801-5.
299. Balkuv Ulutin Ş. Aterosklerozda fibrinolitik mekanizma. *Hematoloji IX*, 1987:48-56.
300. Aktulga AZ, Ulutin ON. Normal ve patolojik durumlarda trombosit fosfolipid dağılımı. *Hematoloji V*, 1975:189-3.
301. Yiğit Ş, Kemahlı S, Akar N, Gürman C, Uzunali Ö, Cin Ş. Fibrinolytic activity in Neonates. *Haemosta-*

- sis 1998;28(Suppl 2):310.
302. Ezer Ü, Yüksel S, Kapağası A, Gürsoy. Haemorrhagic Disease of the Newborn. Haemostasis 1998;28 (Suppl 2):311.
303. Güven KC, Arabacıoğlu F, Aktin E, Ulutin ŞB, Koyuncuoğlu H. The lipolytic, anticoagulant and fibrinolytic activity of heparin fractions. Pharm Ind 1974;36:205-8.
304. Güven KC, Özsoy Y, Ulutin ŞB, Ulutin ON. Anticoagulant, antithrombin and fibrinolytic activities of heparin fractions. Acta Pharmaceutica Turcica 1990; 32:107-11.
305. Berkarda B. The influence of anticoagulants on fibrinolytic activity. New İstanbul Contr Clin Sci 1962;5:186-96.
306. İnceman Ş, Saraçbaşı Z. Platelet osmotic resistans test using phase contrast test. New İstanbul Contr Clin Sci 1962;5:293-311.
307. Frank E, Ulutin ON, Karaca M. Die isolierten und assoziierten athrombien. New İstanbul Contr Clin Sci 1956;4:62-94.
308. Ekren H. The prothrombin consumption test (Quick) and its importance in differential diagnosis of hemorrhagic diathesis. New İstanbul Contr Clin Sci 1951;1:446-50.
309. Quick AJ. Platelets, erythrocyte and tissue thromboplastin. New İstanbul Contr Clin Sci 1964;7:156-63.
310. Karaca M, Akpınar N, Eryöner G, Kabakçı T, Kocabaş A. Comparative studies on blood clotting activity of the arterial and venous blood in normal and venous blood in normal and patients with atherosclerosis. New İstanbul Contr Clin Sci 1967;9:108-13.

Address for Correspondence:

Orhan N. ULUTİN, MD

Levent, Begonya Sokak 6
80620, İstanbul, TURKEY

e-mail: ulutin@superonline.com

Theories of the pathogenesis of atherosclerosis. qTheory of the reaction to damage. As an initial factor of atherogenesis, vascular damage that can be caused by a variety of factors: hyperlipidemia, mechanical stress, stress, immune mechanisms, toxins, viruses or other infectious agents, hemodynamic factors (hypertension, recurrent spasms, irregular turbulent blood flows in the area of branching of blood vessels, etc). Stages of pathogenesis. W Walls of arterioles are considerably thickened due to the accumulation in the intima of homogeneous unstructured masses of hyaline, the lumen is narrowed, sometimes obliterated. The glomeruli are collapsed (collapsed), many are replaced by connective tissue or hyaline masses. The tubules are atrophied. REVIEW ARTICLE Coagulation and the vessel wall in thrombosis and atherosclerosis Marie-Claire Kleinegris, Arina J. ten Cate-Hoek, Hugo ten Cate Laboratory for Clinical Thrombosis and Hemostasis, Department of Internal Medicine, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, The Netherlands Keywords atherosclerosis, coagulation, endothelium, thrombosis, vessel wall Correspondence to: Marie-Claire Kleinegris, MD, Laboratory for Clinical Thrombosis and Hemostasis, Department. Virchow's triad, which comprises changes in the components of the blood, the state of the vessel wall, and the blood flow, was originally proposed for venous thrombosis. For many decades coronary heart disease has retained the first place in the structure of mortality from cardiovascular diseases in Russia (49.9%). Disturbances in the hemostatic system form a permanent hypercoagulable state, which, against the background of atherosclerosis, can lead to thrombotic complications. This article presents the results of a study of the features of the hemostatic system, endothelial cell markers and the carriage of thrombogenic polymorphisms in patients with coronary heart disease at different levels of atherosclerotic lesion of the coronary arteries.